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ABSTRACT OF DISSERTATION

OPIOID USE IN VULNERABLE POPULATIONS
Opioid-related negative health outcomes, such as substance use disorder, misuse,
and overdose deaths, have risen as long-term opioid use has increased. The benefit of using
long-term opioids for pain is yet to be established. The Centers for Disease Control and
Prevention provides guidelines for opioid prescribing in chronic pain, but detailed
recommendations on opioid prescribing for vulnerable populations are missing due to lack
of evidence-based studies. The purpose of this dissertation is to describe patterns and
predictors of opioid use and assess outcomes related to prescribing opioid medications in
vulnerable populations, specifically older adults with various levels of cognitive function,
as well as US adults enrolled in the Medicaid program.
The four projects included in this dissertation used existing data from the National
Alzheimer’s Coordinating Center (2005 and 2017) for the first and second projects and the
Center for Medicare and Medicaid Services––Medicaid enrollment and claims data (20022009), including four US states, Kentucky, Maryland, North Carolina, and Washington,
for the third and fourth projects. The first research project, “Patterns and predictors of
chronic opioid use in older adults: a retrospective cohort study,” shows that chronic opioid
use is more prevalent in participants who are more vulnerable among participants with 65+
age. The second research project, “Comparing the patterns and predictors of opioid use in
older adults with different cognitive status,” shows that the patterns and predictors of
chronic opioid use vary across the cognitive status. The third research project, “An
investigation of predictors of long-term opioid use in Medicaid beneficiaries with HIV who
initiated antiretroviral therapy,” shows that comorbidities and polypharmacy was important
predictors of long-term opioid use in patients with HIV. The fourth research project, “The
effect of long-term opioid use on healthcare utilization in Medicaid beneficiaries with HIV
who initiated antiretroviral therapy” shows long-term opioid use is associated with
increased emergency department admissions and HIV-related hospitalization and
decreased discontinuation of standard antiretroviral therapy in HIV-diagnosed Medicaid
beneficiaries.
The results from this dissertation provide a better understanding of utilization
patterns and effects of opioid use in vulnerable populations needed to improve the riskbenefit assessment for opioid use in these populations.
KEYWORDS: Persistent Opioid Use, Older Adults, Older Adults with Cognitive
Impairment, HIV Patients
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CHAPTER 1. INTRODUCTION
The prevalence of long-term opioid use in the US increased three times in 20132014 compared to 1999-2000, likely due to an increase in chronic pain reporting. [1]. Using
the 2016 National Health Interview Survey data (NHIS), the Centers for Disease Control
and Prevention (CDC) reported that one in five of the US adults, which represents 50
million people, experienced chronic pain, with 8.0% of the US adults suffering from highimpact chronic pain [2]. Earlier NIHS data from 2012 reported that about 25.3 million
people (i.e., 11.2% of the adult population in the US) suffered from chronic pain, thus
suggesting a 100% increase in reporting in 2016 [3].
Despite the increase in opioid use, the effectiveness of long-term opioid therapy
for chronic pain is still questionable. A 2015 systematic review paper concluded that the
evidence is limited to determine the effectiveness of long-term opioid therapy for chronic
pain [4]. In 2018, a randomized clinical trial was performed to examine the effect of opioid
therapy over 12 months on improving pain for patients with moderate to severe pain
compared to non-opioid medication therapy [5]. The results have indicated that the painrelated function over 12 months was no different in patients with long-term opioid
medications compared to patients with non-opioid medications [5]. At this time, more
studies are required to determine the benefits of using opioid treatments for chronic pain
patients.
While more evidence is needed to determine the effectiveness of long-term opioid
use, there is growing evidence for the risk and adverse effects of long-term opioid use.
From a randomized clinical trial, the long-term opioid treated group has shown
significantly more analgesic-related hospitalizations, emergency department (ED) visits,
1

and falls than the non-opioid treated group [5]. Furthermore, several studies have reported
that long-term opioid use was associated with risks, such as opioid abuse or dependence
[6-8], overdose [9], and fractures [10]. In 2017, the CDC reported that 67.8% of all drug
overdose deaths were related to opioid use [11]. The increased usage of long-term opioids
has shown a parallel increase in the rate of drug overdose death at the same time frame [4,
12]. A retrospective cohort study has reported that the risk of overdose rates was increased
in long-term opioid users with higher doses compared to the long-term opioid use with
lower doses [9].
To address the increasing concern about the balance of the risk and benefit of using
opioids chronically, the CDC issued prescribing guidelines for opioids in patients suffering
from chronic pain in 2016 [13]. This guiding document includes 12 recommendations, and
emphasizes the need to consider nonpharmacologic therapy and nonopioid pharmacologic
therapy for chronic pain before opioid therapy. Based on the CDC guidelines, opioid
therapy should be considered only when the expected benefits in addressing chronic pain
and function overweigh the risks. In order to update the guideline in the future, Dowell et
al. urge more studies are needed to fill the evidence gaps. Moreover, recently, the
American Medical Association urges that CDC guidelines need to provide individualized
guidance for patients with pain [14].
Notably, the recommendations in the CDC guidelines apply to patients 18 years
and older with chronic pain excluding active cancer treatment, palliative care, and end-oflife care, but lack detailed guidance on opioid prescribing in vulnerable populations, such
as elderly, children, underinsured, racial or ethnic minorities, and those with human
immunodeficiency virus (HIV), chronic disease, or mental disease. The guidelines
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recommend increasing monitoring to minimize the risks of opioids in older adults and
discuss with both caregiver and patients to manage opioid therapy for older adults with
cognitive limitations [13]. Older adults are more sensitive to negative outcomes (e.g.,
cognitive impairment and falls) from opioids, in part due to age-related decreases in liver
and kidney function and polypharmacy [15-17]. Older adults with cognitive impairment
have a potential risk of adding the burden of cognitive impairment and the risk of other
adverse events from opioids. Also, they are in a high risk of undertreating the pain due to
inherent difficulties in assessing and treating pain [18]. Moreover, since patients with HIV
have a high rate of drug abuse history [19] and several studies have reported that opioids
affect the immune functions [20, 21], detailed guidelines are required to treat these patients
with pain. However, since yet little is known about using long-term opioids in a vulnerable
population, detailed guidance on the use of long-term opioids in this population is missing.
The research projects in this dissertation provide the information of using long-term opioid
in vulnerable populations, including older adults, older adults with different cognitive
status, and patients with HIV and suggest the future directions for having more evidencebased studies related to this population.
Chapter Two, “Patterns and predictors of chronic opioid use in older adults: a
retrospective cohort study,” addresses the patterns of the longitudinal opioid utilization in
older adults using group-based trajectory models (GBTM) and identifies predictors
associated with the trajectories indicating long-term use from the National Alzheimer’s
Coordinating Center (NACC) data (2005-2017). This study is the first that has investigated
the longitudinal trajectories of opioid use in older adults, as well as participant
characteristics associated with trajectory membership. The major finding from this project
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is that long-term opioid use is more frequent in vulnerable participants (i.e., older age,
female sex, with multiple comorbidities, and polypharmacy).
Chapter Three, “Comparing the patterns and predictors of opioid use in older adults
with different cognitive status,” compares the longitudinal opioid use in 65 years and older
adults with normal, mildly impaired cognition, and dementia using NACC data (20052017). The results in this project present that the patterns and predictors of trajectories for
any opioid use varied across the cognitive status. Two medical conditions––cardiovascular
disease and urinary incontinence––are associated with incident chronic-use vs. non-use for
participants with dementia; however, with respect to participants with normal cognition,
factors including demographics (i.e., race, type of residence, and education), medical
condition (urinary incontinence), medication use (polypharmacy and using antidepressant
agent) are associated with incident chronic-use vs. non-use.
Chapter Four, “An investigation of predictors of long-term opioid use in Medicaid
beneficiaries with HIV who initiated antiretroviral therapy,” identifies the predictors of
long-term opioid use in patients with HIV using Medicaid data (2002-2009) from four US
states [Kentucky, Maryland, North Carolina, and Washington]. The results from this
project show that comorbidities and polypharmacy are important predictors of long-term
opioid use in patients with HIV after initiating combination antiretroviral therapy (cART).
Chapter Five, “The effect of long-term opioid use on healthcare utilization in
Medicaid beneficiaries with HIV who initiated antiretroviral therapy,” examines the risk
of ED admissions, HIV-related hospitalizations, discontinuation of and switching standard
cART associated with long-term opioid use in patients with HIV. The major founding from
this research project is that long-term opioid uses are associated with increased risk of ED
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admissions and HIV-related hospitalizations, and decreased risk of discontinuation of
ART.
The last Chapter Five summarizes the four research projects, discusses limitations,
and provides further directions to improve the guidelines of long-term opioid use for
vulnerable populations.
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CHAPTER 2. PATTERNS AND PREDICTORS OF CHRONIC OPIOID USE IN
OLDER ADULTS: A RETROSPECTIVE COHORT STUDY
Abstract
Background: Given the controversy around the effectiveness of opioid treatment for
chronic pain and the lack of detailed guidance for prescribing opioids in older adults, the
objectives of this study were to estimate the trajectories and predictors of opioid use in
older adults.
Methods: Data were extracted from the National Alzheimer’s Coordinating Center (20052017). Group-based trajectory modeling was used to identify the patterns of opioid use
(any or strong) among participants age 65+. We used multivariable logistic regression with
backward selection to evaluate demographics and comorbidities as potential predictors of
trajectory membership.
Results: Among 13,059 participants, four trajectories were identified for the use of both
any opioids and strong opioids (minimal-users, incident chronic-users, discontinuingusers, and prevalent chronic-users). For any opioids, female sex (adjusted odds ratio=1.23;
95% confidence interval= 1.03-1.46), black vs. white (1.47; 1.18-1.82), year of education
(0.96; 0.94-0.99), type of residence (independent group vs. private: 1.77; 1.38-2.26, care
facility vs. private: 1.89; 1.20- 2.97), hypertension (1.44; 1.20-1.72), cardiovascular
disease (1.30; 1.09-1.55), urinary incontinence (1.45; 1.19-1.78), dementia (0.73; 0.570.92), number of medications (1 to 4 vs. none: 0.48; 0.36-0.64, 5 or more vs. none: 0.67;
0.50-0.88), and antidepressant agent (1.38; 1.14-1.67) were associated with incident
chronic-use vs. non-use. For strong opioids, female sex (1.27; 1.04-1.56), type of residence
(independent group vs. private: 1.90; 1.43-2.53, care facility vs. private: 2.37; 1.44-3.90),
current smoking (1.68; 1.09-2.60), hypertension (1.49; 1.21-1.83), urinary incontinence
6

(1.45; 1.14-1.84), dementia (0.73; 0.55-0.97), number of medications (1 to 4 vs. none: 0.46;
0.32-0.65, 5 or more vs. none: 0.59; 0.42-0.83), and antidepressant agent (1.55; 1.24-1.93)
were associated with incident chronic-use vs. non-use.
Conclusion: Given that chronic opioid use was more prevalent in participants who were
more vulnerable (i.e., older age, with multiple comorbidities, and polypharmacy), further
studies should evaluate the safety and efficacy of using opioids in this population.
2.1

Introduction
Over 50% of the elderly population reported pain in the United States (US) in 2011,

and about 75% of those reported pain in multiple sites [22]. Although chronic pain is
prevalent in older adults, appropriate treatment is challenging for this population due to the
high rate of polypharmacy and potential of adverse events [17]. Older adults with dementia
may be especially vulnerable due to inherent difficulties in assessing and treating pain [18,
23, 24]. Long-term (90 days) opioid prescriptions have dramatically increased over the
past decade, though the effectiveness of this therapy for chronic pain is yet to be established
[4, 5]. The prevalence of long-term opioid use in US adults increased from 1.8% in 19992000 to 5.4% in 2013-2014 [25]. Among these long-term opioid users, 25% were adults
age 65 years or older [25]. Opioid-related negative outcomes, such as addiction, misuse,
and overdose deaths, have also risen [15, 16, 26, 27]. Long-term opioid use has also been
associated with opioid overdose-related hospitalization in older adults [28].
A recent study in Australia showed that opioid initiation with a transdermal
formulation, higher oral morphine equivalents, older age, history of mental health
comorbidities, use of non-opioid analgesics, and use of benzodiazepines were the
predictors of persistent prescription opioid in 18 years and older adults [29]. A prospective
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study with participants in a large nonprofit health care system in Washington State reported
that patients’ expectations of long-term opioid use was the predictor of 30 or more days
use of opioids [30]. Although several studies reported the predictors of chronic opioid use
in different population, there is still limited study that examined the predictors of long-term
opioid use in older adults in the US population. Older adults are more sensitive to negative
outcomes (e.g., cognitive impairment, falls) from opioids, in part due to age-related
decreases in liver and kidney function and polypharmacy [15-17, 27]. The Centers for
Disease Control and Prevention (CDC) recently issued guidelines aimed at improving the
safety and effectiveness of chronic pain treatment [13, 31]. These guidelines recommend
increasing monitoring to minimize the risks of opioids in older adults, yet lack detailed
guidance on opioid prescribing [13, 31]. Identifying the characteristics associated with
opioid use in older adults can help identify factors that could improve risk-benefit
assessment and prevent inappropriate use. Therefore, the purpose of this study was to
investigate patterns of longitudinal opioid utilization in older adults using group-based
trajectory models and to identify predictors associated with the trajectories indicating
chronic use.
2.2

Methods
Study participants
Study data were drawn from the National Alzheimer’s Coordinating Center’s

(NACC) Uniform Data Set (UDS), which comprises participants enrolled in longitudinal
studies at NIA-funded Alzheimer’s Disease Centers (ADC) throughout the US.
Participants including subjects with a range of normal to dementia cognitive status are
recruited from clinician referral, self-referral by patients or family members, active
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recruitment, and volunteers. The data are collected from the subjects and their coparticipants annually by trained clinicians and other ADC research personnel until they are
deceased or decline to participate. Data collected at initial and annual follow-up visits
include sociodemographic characteristics, family history, medical history, neurological
evaluations, and medication use information [32-34]. For this study, we included
participants from 38 ADCs with data available in the September 2017 UDS data freeze,
meeting the following inclusion criteria: (1) 65 years or older at their initial UDS visit, and
(2) medication data recorded at every visit. Participants with fewer than three visits were
excluded to facilitate assessing trajectory trends with quadratic components, and since
opioid medications are highly prevalent in participants with cancer history [35], these
participants were also excluded (Figure 2.1). ADC study procedures are approved by local
Institutional Review Boards (IRBs), and all participants provided written informed
consent. Research using the NACC database is approved by the University of Washington
IRB. Because the NACC data are de-identified, no additional IRB approval was necessary
for this secondary data analysis.
Opioid use assessment
Medication

information

was

provided

by

the

participant

and/or

the

caregiver/legally authorized representative and was based on each participant’s reported
medication use within two weeks of each study visit. In assessing opioid use, opioid
medications used as antitussives were not considered. Participants were considered to be
“any opioid” users if they reported use of any opioid analgesic medications, and “strong
opioid” users were defined among any opioid users if they reported use of opioid analgesics
stronger than or equal to morphine’s potency [36, 37] (e.g., buprenorphine, fentanyl,
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hydrocodone, hydromorphone, methadone, morphine, opium, oxycodone, oxymorphone)
(Table 2.1s).
Participant characteristics
Baseline characteristics of interest were recorded at the participant’s initial UDS
visit. Demographic information included age at enrollment (reference category [ref]: 6574 years), sex (ref: male), race (ref: white), years of education, and type of residence (ref:
single- or multiple-family private dwelling). Self-reported medical history information
included current smoking, as well as ever-history of alcohol abuse, and other abused
substances; hypertension, diabetes, urinary incontinence, and cardiovascular conditions.
Medication information included number of medications reported (excluding opioid
analgesics); use of nonsteroidal anti-inflammatory medication (NSAID), antidepressant
agent, antipsychotic agent (including miscellaneous antipsychotics, psychotherapeutic
combinations, phenothiazine psychotics, thioxanthenes, and atypical antipsychotics), and
anxiolytic, sedative, or hypnotic agent (including barbiturates and benzodiazepines, and
miscellaneous anxiolytics, sedatives, and hypnotics). Reference category for all medical
history and medication variables was the absence of condition or medication use. Cliniciandetermined agitation (ref: no agitation) and cognitive status (ref: no dementia) were also
included in the analysis [see Table 2.2s for detailed descriptions].
Statistical analysis
Group-based trajectory models (GBTM) [38, 39] were used to identify participants
with similar longitudinal patterns of opioid analgesic use. With this approach, latent
trajectories are estimated by the model, and every individual is assigned a probability of
belonging to each trajectory, with total probability of membership summing to 1.0; we used

10

maximum probability assignment to determine group membership. The shapes of each
trajectory are defined by polynomial terms (cubic, quadratic, or linear). Since the time scale
was study time, and participants could have up to 12 visits, follow-up was truncated when
more than 95% of participants did not have data available for a particular visit. As a result,
data from visits 11 and 12 were not included in the analysis.
Models considering between 2 and 6 trajectories were fit to the data, and the optimal
final model was determined by the Bayesian Information Criterion (BIC) with the least
negative value [40, 41]. In addition, for judging model adequacy, Nagin proposes that the
average posterior probability of membership in the assigned group should be greater than
0.7 [40, 41].
Once optimal GBTM models were selected, we assessed face validity by tabulating
the proportion of total study visits in each trajectory group where opioid analgesic use was
reported (e.g., participants assigned to the higher use groups should have higher proportion
of visits where opioid analgesic use was reported). We then used multivariable logistic
regression with backward selection to identify participant characteristics significantly
associated with trajectory group membership. Our preliminary analyses indicated that there
were participants who could be described as chronic users, such that they reported using
the drugs at most visits. Since our primary interest was in identifying risk factors for this
group of participants, the outcome for the logistic models was membership in a chronic
user group vs. membership in a group that did not use opioid analgesics chronically.
Participants with missing values, including “unknown”, were excluded from this
analysis with the exception of type of residence, which had a large number of participants
in the “unknown or other” category (>600). Here, we treated unknown/other as a category.
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Adjusted odds ratios (ORadj) with 95% confidence intervals (CI) were obtained from the
full and reduced models. To identify the best fitting logistic models, Akaike’s Information
Criterion (AIC) values were compared between full and reduced models. All data analyses
were conducted using SAS 9.4®, and 0.05 was set as the significance level. PROC TRAJ
[38] was used to estimate GBTM, and PROC LOGISTIC was used to fit the logistic
regression models.
2.3

Results
A total of 13,059 participants were included in our analyses after applying inclusion

and exclusion criteria (Figure 2.1). The mean (SD) number of follow-up visits was 5.4 (2.2)
years (range 3 to 10). The mean (SD) baseline age was 75.8 (6.9) years. A majority of
participants were female (56.7%), white (83.1%), and resided in private dwellings (89.9%).
The most common comorbidity was hypertension (55.0%), and 55.8% of participants
reported taking 5 or more medications. At the initial visit, there were 498 (3.8%) users of
any opioid and 284 (2.2%) users of strong opioids (Tables 2.1 and 2.2).
Using GBTM, four trajectories were identified for both any opioid use and strong
opioid use (Figure 2.2). The optimal number of trajectories was determined based on the
BIC in combination with the requirement that the average posterior probability in all
assigned trajectory groups was at least 0.70 [40, 41]. The shapes of the trajectories for any
opioid use were quadratic or cubic, and the parameter estimates of the quadratic or cubic
function for each trajectory were all statistically significant (Table 2.3s). For strong opioid
use, the shapes of the trajectories were all quadratic, and the parameter estimates of the
quadratic function for each trajectory were significant in 3 of the 4 groups. The final
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optimal models were adequate based on the criterion of the average posterior probability
[40, 41] (Table 2.3s).
GBTM for any opioids
A majority of participants (90.4%) were assigned to the “minimal-users” group,
who reported no use or low use over time. Participants (5.0%) who did not report opioid
use at their first visit, but initiated use during the study period and continued their use
during follow-up were assigned to the “incident chronic-users” group. “Discontinuingusers” were participants who used opioids at the first visit but discontinued during followup (2.2%). “Prevalent chronic-users” (2.4%) were participants who reported opioid use at
baseline and consistently during follow-up (Figure 2.1). The median percentage (IQR) of
UDS visits with any opioid use were 0% (0-0), 33.3% (25.0-40.0), 40.0% (33.3-60.0), and
85.7% (75.0-100) for minimal-users, incident chronic-users, discontinuing-users, and
prevalent chronic-users, respectively. Participant characteristics for each group are
presented in Table 2.1.
GBTM for strong opioids
Similar trajectories—minimal-users (94.3%), incident chronic-users (3.4%),
discontinuing-users (0.9%), and prevalent chronic-users (1.4%)—were identified for use
of strong opioids. The median percentage (IQR) of UDS visits with strong opioid use were
0% (0-0), 33.3% (25.0-40.0), 50.0% (33.3-60.0), and 83.3% (70.0-100.0) for minimalusers, incident

chronic-users, discontinuing-users, and prevalent chronic-users,

respectively. Participant characteristics for each group are presented in Table 2.2.
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Predictors of prevalent chronic-use trajectory membership
Multivariable logistic regression models were used to identify the predictors of
prevalent chronic-use trajectory membership compared to discontinuing-users or minimalusers for both any and strong opioids. All variables listed in Table 2.1 were considered for
inclusion (full model) (Tables 2.4 and 2.5), and the reduced models are reported in Tables
2.3 and 2.4. After backward selection, urinary incontinence was negatively associated with
prevalent chronic-use vs. discontinuing-use for both any opioids (ORadj=0.66 [95%
CI=0.45, 0.98]) and strong opioids (0.45 [0.25, 0.80]).
Several factors emerged as significant predictors of prevalent chronic-use vs.
minimal-use in both models (any opioid and strong opioids): age (any opioid: 1.83 [1.28,
2.61]; strong opioids:2.10 [1.34, 3.28]), female sex (1.76 [1.35, 2.30]; 1.71[1.22, 2.40]),
black vs. white (1.92 [1.41, 2.61]; 1.97 [1.34, 2.91]), independent group living vs. private
living (1.74 [1.21, 2.49]; 1.68 [1.06, 2.65]), care facility living vs. private living (2.02 [1.07,
3.83]; 3.46 [1.73, 6.94]), 5 or more medications vs. none (2.52 [1.25, 5.08]; 4.89 [1.53,
15.65]), use of antidepressant agent (1.89 [1.46, 2.44]; 1.89 [1.36, 2.63]), use of anxiolytic,
sedative, or hypnotic agent (2.26 [1.69, 3.02]; 2.51 [1.76, 3.57]), and dementia (0.46 [0.32,
0.68]; 0.39 [0.23, 0.65]) (Tables 2.3 and 2.4).
Predictors of incident chronic-use trajectory memberships
Four multivariable logistic regression models were used to identify predictors
associated with incident chronic-users compared to discontinuing-users or minimal-users
for both any and strong opioid groups. Use of anxiolytic, sedative, or hypnotic agent (any
opioids: 0.57 [0.39, 0.83]; strong opioids: 0.53 [0.31, 0.90]), 1 to 4 medications vs. none
(0.26 [0.11, 0.62]; 0.12 [0.02, 0.95]), and 5 or more medications vs. none (0.17 [0.07, 0.39];
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0.07 [0.01, 0.52]) were significant predictors of incident chronic-use vs. discontinuing-use
in both models (Tables 2.3 and 2.4).
Several factors emerged as significant predictors of incident chronic-use vs.
minimal-use in both models (any opioid and strong opioids): female sex (any opioid: 1.23
[1.03, 1.46]; strong opioids: 1.27 [1.04, 1.56]), independent group living vs. private living
(1.77 [1.38, 2.26]; 1.90 [1.43, 2.53]), care facility living vs. private living (1.89 [1.20,
2.97]; 2.37 [1.44, 3.90])hypertension (1.44 [1.20, 1.72]; 1.49 [1.21, 1.83]), urinary
incontinence (1.45 [1.19, 1.78]; 1.45 [1.14, 1.84]), use of antidepressant agent (1.38 [1.14,
1.67]; 1.55 [1.24, 1.93]), 1 to 4 medications vs. none (0.48 [0.36, 0.64]; 0.46 [0.32, 0.65]),
5 or more medications vs. none (0.67 [0.50, 0.88]; 0.59 [0.42, 0.83]) and dementia (0.73
[0.57, 0.92]; 0.73 [0.55, 0.97]) (Tables 2.3 and 2.4).
2.4

Discussion
This study investigated the patterns of use and the predictors of each trajectory over

10 years of follow-up for use of opioid analgesics (any opioid or strong opioids) in older
adults. The prevalence of any opioid use (3.8%) at enrollment was lower than that reported
in a previous study (6.5%) using National Health and Nutritional Examination Survey
(NHANES) from 1999 to 2014 [25]. In addition, the prevalence of any opioid use in our
study was lower than that reported in other countries. A previous study from Canada has
reported that the prevalence of prescription opioid use was 16.7% in the population aged
65+ in 2009 [42]. A recent study of Australians conducted by Lalic et al. has reported that
the prevalence of prescription opioid analgesic use in people without cancer (ages 18-99
years) was 15.37% in 2016-2017 [43]. Another study has examined that 14.1% of residents
(aged 65+) in the State of Victoria, Australia, filled the prescription of oxycodone in 2013
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[44]. This could be due to the different definition of identifying opioid use (reported
medications used within two weeks of visit vs. prescription opioid use in the past 30 days)
and using different study population. There were four longitudinal trends—minimal-users,
incident chronic-users, discontinuing-users, and prevalent chronic-users—for use of both
any and strong opioids. We found that participants who were older, female, black, residing
in independent group living or care facilities, or taking antidepressant agents were more
likely to be chronic-users compared to minimal-users in both the “any opioid” and “strong
opioid” user groups. These results are consistent with previous studies that reported that
older adults and women experience pain more frequently than younger adults and men [28,
45-47], and that older women have a higher prevalence of long-term opioid use [48]. Also,
previous studies have shown that long-term opioid use is highly prevalent in nursing home
residents compared to people in a community setting [49], and having depression was
associated with long-term opioid use in older adults [28].
We found that taking anxiolytic, sedative, or hypnotic agents (including
barbiturates and benzodiazepines) was significantly associated with prevalent chronic-use
in both the any opioid and strong opioid user groups compared to minimal-use. We also
observed that the prevalence of taking benzodiazepines was higher in prevalent chronicusers (2.9%) than in minimal-users (0.7%). In a recent study including adult participants
of the NHANES, long-term use of opioids was associated with concurrent benzodiazepine
use [25]. Similarly, a study from Australia reported that previous use of benzodiazepines
was one of the predictors of persistent opioid use [29]. Considering the overdose risk of
co-prescribing benzodiazepine and opioids [50], the CDC guidelines suggest avoiding the
use of opioids and benzodiazepines together [13, 31]. Therefore, further studies are needed
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to investigate the effect of using opioids and benzodiazepines together on opioid-related
adverse outcomes in older adults.
We found that patients with dementia were less likely to become chronic users of
either any or strong opioids compared to non-users. This trend might be due to inherent
difficulties in assessing and treating pain in patients with dementia [18, 24], as well as
potential concerns about the added burden of cognitive impairment and risk of other
adverse events from opioids. Given the concern about serious problems (e.g., depression,
anxiety, and agitation) that could result from under-treating pain in older adults [47, 5154], future studies are required to thoroughly address the patterns of opioid use in patients
with dementia.
Reporting a higher number of medications was positively associated with prevalent
chronic-use of both any opioid and strong opioids; however, with respect to incident
chronic-use, the results showed that participants with higher number of medications were
less likely to be incident chronic-users compared to discontinuing-users or minimal-users.
Since ADC participants may be more likely to receive medical care than the general
population through their contacts with ADC clinicians, there is a possibility that the
participants with polypharmacy were monitored more closely with regard to newly
prescribed opioids. Thus, this result may not be generalizable to all older adults in the US.
Neither comorbidities nor number of medications significantly predicted prevalent
chronic-use vs. discontinuing use. A recent prospective study concluded that neither
baseline chronic pain risk score nor depression were predictors of long-term opioid use;
rather, a patient’s expectation of long-term opioid use was the strongest predictor [30]. In
a recent study, long-term opioid use was significantly associated with physicians who have
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high-intensity of prescribing opioids [55]. We also examined group percentages of
discontinuing- and chronic-users among the different ADCs (Table 2.6s) and observed that
some centers had a higher proportion of discontinuing users than others. Thus, it is possible
that clinicians at different ADCs implement varying approaches in the management of pain
and the de-escalation and discontinuation of opioids in participants who use these
medications chronically. Future studies that include other factors (e.g., clinician
characteristics or patient’s expectation) are needed to fully understand how the prevalent
chronic opioid-user group is different from the discontinuing group.
This study has several limitations. First, because opioids were identified by reported
medications used within two weeks of UDS visit, we could not classify participants by
continuous long-term use of opioids. Given the short exposure window, participants could
be misclassified if they used opioids only between visits. However, with up to 10 years of
annual assessments, we believe that we have meaningful information regarding
longitudinal use patterns. Additionally, ADC participants tend to be highly educated, which
may limit generalizability [32]. Also, participants who were excluded from the study had
a higher rate of comorbidities and a higher rate of using any opioid/strong opioids at
baseline (Table 2.7s). The selection bias from this criterion may result in an underestimate
of opioid usage in this cohort. However, since the mean of visit number for each trajectory
group in any opioid users was similar (minimal user: 5.38; incident chronic user: 5.75;
discontinuing-user: 5.13; prevalent chronic user: 5.06), participants with less of follow up
didn’t affected the participants being in their trajectory group. Finally, we did not consider
time-varying covariates, which may have resulted in different associations.
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In conclusion, the present study showed that potentially inappropriate opioid use
was disproportionately prevalent among vulnerable NACC participants (i.e., older age,
with multiple comorbidities and polypharmacy). Further studies are required to thoroughly
address the risk and benefit of using opioids in older adults, and it is essential to provide
evidence-based guidelines for opioid use in this population.

19

Table 2.1. Baseline characteristics across trajectory groups of any opioid use
Baseline Characteristics
Pattern of Any Opioid Use
Minimal

Discontinuing

Incident chronic

Prevalent chronic

(N=11,806)

(N=287)

(N=657)

(N=309)

65-74

5,479 (46.4)

131 (45.6)

266 (40.5)

132 (42.7)

75-84

4,976 (42.2)

108 (37.6)

294 (44.8)

121 (39.2)

85+

1,351 (11.4)

48 (16.7)

97 (14.8)

56 (18.1)

Female

6553 (55.5)

203 (70.7)

423 (64.4)

226 (73.1)

White

9,869 (83.7)

216 (75.5)

508 (77.6)

236 (76.6)

Black

1,453 (12.3)

59 (20.6)

131 (20.0)

67 (21.8)

Othera

464 (3.9)

11 (3.9)

16 (2.4)

5 (1.6)

15.3 (3.4)

14.5 (3.6)

14.6 (3.4)

14.5 (3.4)

10,371 (87.9)

247 (86.1)

531 (80.8)

243 (78.6)

Independent groupc

854 (7.2)

28 (9.8)

88 (13.4)

44 (14.2)

Care facilityd

228 (1.9)

5 (1.7)

25 (3.8)

14 (4.5)

Unknown

353 (3.0)

7 (2.4)

13 (2.0)

8 (2.6)

Current smoking

377 (3.2)

18 (6.3)

26 (4.0)

17 (5.5)

Ever alcohol abuse

513 (4.4)

19 (6.6)

31 (4.7)

19 (6.2)

Baseline age

Race
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Education, mean (SD)
Type of Residence
Privateb

Table 2.1. (continued)
Ever other abused

63 (0.5)

4 (1.4)

4 (0.6)

5 (1.6)

652 (5.5)

10 (3.5)

31 (4.7)

16 (5.2)

Ever hypertension

6,326 (53.7)

200 (69.7)

432 (65.9)

205 (66.6)

Ever diabetes

1,401 (11.9)

54 (18.8)

104 (15.8)

59 (19.2)

Ever cardiovascular

2,953 (25.3)

82 (28.9)

214 (32.8)

103 (33.6)

1,742 (14.8)

79 (27.5)

147 (22.4)

62 (20.1)

2,047 (17.3)

41 (14.3)

103 (15.7)

38 (12.3)

898 (7.6)

6 (2.1)

76 (11.6)

10 (3.2)

1 to 4

4,489 (38.0)

58 (20.2)

170 (25.9)

61 (19.7)

5 or more

6,419 (54.4)

223 (77.7)

411 (62.6)

238 (77.0)

Antidepressant agent

2,645 (22.4)

109 (38.0)

184 (28.0)

121 (39.2)

Antipsychotic agent

292 (2.5)

4 (1.4)

24 (3.7)

11 (3.6)

Anxiolytic, sedative,

1,134 (9.6)

64 (22.3)

83 (12.6)

73 (23.6)

4,022 (34.1)

116 (40.4)

219 (33.3)

143 (46.3)

substances
Agitation

disease
Ever urinary
incontinence
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Dementia diagnosis
Number of medicationse
0

or hypnotic agent
NSAID use

Table 2.1. (continued)
Any opioid use

121 (1.0)

162 (56.5)

9 (1.4)

206 (66.7)

Strong opioid use

67 (0.6)

90 (31.4)

6 (0.9)

121 (39.2)

(All results presented are N (%) unless otherwise noted)
Abbreviations: SD, standard deviation; NSAID, nonsteroidal anti-inflammatory medication
Note: a=American Indian, Alaska Native, Native Hawaiian, Other Pacific Islander, Asian, or Other; b=single-or multiple
family private living; c=retirement community, or independent group living; d=assisted living, nursing home, or hospital;
e=number of opioids was excluded from the total number of medications.
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Table 2.2. Baseline characteristics across trajectory groups of strong opioid use
Baseline
Pattern of strong opioid use
Characteristics
Incident

Prevalent

chronic

chronic

(N=444)

(N=182)

57 (49.1)

176 (39.6)

76 (41.8)

5,192 (42.2)

40 (34.5)

197 (44.4)

70 (38.5)

85+

1,426 (11.6)

19 (16.4)

71 (16.0)

36 (19.8)

Female

6,904 (56.1)

79 (68.1)

289 (65.1)

133 (73.1)

White

10,232 (83.2)

92 (80.0)

362 (81.7)

143 (78.6)

Black

1,584 (12.9)

20 (17.4)

70 (15.8)

36 (19.8)

Othera

479 (3.9)

3 (2.6)

11 (2.5)

3 (1.7)

15.2 (3.4)

14.6 (3.7)

14.9 (3.4)

14.6 (3.1)

10,806 (87.7)

99 (85.3)

351 (79.1)

136 (74.7)

Independent groupc

911 (7.4)

12 (10.3)

64 (14.4)

27 (14.8)

Care facilityd

236 (1.9)

4 (3.5)

20 (4.5)

12 (6.6)

Unknown

364 (3.0)

1 (0.9)

9 (2.0)

7 (3.9)

Current smoking

391(3.2)

10 (8.7)

23 (5.2)

14 (7.7)

Ever alcohol abuse

537 (4.4)

13 (11.2)

20 (4.5)

12 (6.6)

65 (0.5)

2 (1.7)

6 (1.4)

3 (1.7)

672 (5.5)

4 (3.5)

26 (5.9)

7 (3.9)

Ever hypertension

6,673 (54.3)

84 (72.4)

287 (64.8)

119 (65.4)

Ever diabetes

1,505 (12.3)

23 (19.8)

62 (14.0)

28 (15.4)

3,112 (25.5)

40 (34.8)

139 (31.5)

61 (33.9)

Minimal

Discontinuing

(N=12,317)

(N=116)

65-74

5,699 (46.3)

75-84

Baseline age

Race

Education, mean (SD)
Type of Residence
Privateb

Ever other abused
substances
Agitation

Ever cardiovascular
disease
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Table 2.2. (continued)
Ever urinary

1,857 (15.1)

37 (31.9)

101 (22.8)

35 (19.2)

2,124 (17.2)

16 (13.8)

69 (15.5)

20 (11.0)

936 (7.6)

1 (0.9)

50 (11.3)

3 (1.7)

1 to 4

4,599 (37.3)

21 (18.1)

119 (26.8)

39 (21.4)

5 or more

6,782 (55.1)

94 (81.0)

275 (61.9)

140 (76.9)

Antidepressant agent

2,795 (22.7)

51 (44.0)

138 (31.1)

75 (41.2)

Antipsychotic agent

307 (2.5)

3 (2.6)

16 (3.6)

5 (2.8)

1,219 (9.9)

29 (25.0)

56 (12.6)

50 (27.5)

4,235 (34.4)

42 (36.2)

141 (31.8)

82 (45.1)

Any opioid use

259 (2.1)

81 (69.8)

28 (6.3)

130 (71.4)

Strong opioid use

82 (0.7)

78 (67.2)

3 (0.7)

121 (66.5)

incontinence
Dementia diagnosis
Number of
medicationse
0

Anxiolytic, sedative,
or hypnotic agent
NSAID

(All results presented are N (%) unless otherwise noted)
Abbreviations: SD, standard deviation; NSAID, nonsteroidal anti-inflammatory
medication.
Note: a= American Indian, Alaska Native, Native Hawaiian, Other Pacific Islander,
Asian, or Other; b=single-or multiple family private living; c=retirement community, or
independent group living; d=assisted living, nursing home, or hospital; e= number of
opioids was excluded from the total number of medications.
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Table 2.3. Predictors associated with chronic-use (prevalent or incident) vs. discontinuing-use or minimal-use of any opioid in
multivariable logistic regression model (reduced models adjusted for the covariates retained by backward selection)
Prevalent chronic-use vs.
Incident chronic-use vs.
a
b
discontinuing-use
minimal use
discontinuing-usec
minimal-used
Baseline age
65-74
Ref.
75-84
1.11 (0.85, 1.44)
1.83 (1.28, 2.61)
85+
1.76 (1.35, 2.30)
0.72 (0.52, 0.98)
1.23 (1.03, 1.46)
Female vs. male
Race
White
Ref.
Ref.
Black
1.92 (1.41, 2.61)
1.47 (1.18, 1.82)
0.44 (0.18, 1.08)
0.62 (0.37, 1.04)
Other
0.95 (0.91, 0.98)
0.96 (0.94, 0.99)
Education (1-year difference)
Type of Residence
Private
Ref.
Ref.
Independent group
1.74 (1.21, 2.49)
1.77 (1.38, 2.26)
2.02
(1.07,
3.83)
1.89 (1.20, 2.97)
Care facility
Unknown
Hypertension
Diabetes
Cardiovascular disease
Urinary incontinence

-

0.88 (0.42, 1.81)
1.44 (1.05, 1.97)
-

-

0.66 (0.37, 1.19)
1.44 (1.20, 1.72)
1.30 (1.09, 1.55)

0.66 (0.45, 0.98)

-

-

1.45 (1.19, 1.78)

-

Ref.
1.33 (0.65, 2.71)
2.52 (1.25, 5.08)

Ref.
0.26 (0.11, 0.62)
0.17 (0.07, 0.39)

Ref.
0.48 (0.36, 0.64)
0.67 (0.50, 0.88)

Number of medications
None
1 to 4
5 or more

Table 2.3. (continued)
Antidepressant agent
Anxiolytic, sedative, or
hypnotic agent
NSAID

-

1.89 (1.46, 2.44)
2.26 (1.69, 3.02)

0.57 (0.39, 0.83)

1.38 (1.14, 1.67)
-

-

1.36 (1.06, 1.75)

-

-

0.46 (0.32, 0.68)
0.73 (0.57, 0.92)
Dementia
Note: Where the reference category is not specified, the comparison is either yes vs. no or ever vs. never. a=Number of
observations used in the model is 578 (prevalent chronic-user: 298 and discontinuing-user: 280); b=Number of observations used
in the model is 11,458 (prevalent chronic-user: 298 and minimal-users: 11,458); c= Number of observations used in the model
is 920 (incident chronic-user: 640 and discontinuing-user: 280); d= Number of observations used in the model is 12,098 (incident
chronic-user: 640 and minimal-users: 11,458
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Table 2.4. Predictors associated with chronic-use (prevalent or incident) vs. discontinuing-use or minimal-use of strong opioid
in multivariable logistic regression model (reduced models adjusted for the covariates retained by backward selection)
Prevalent chronic-use vs.
Incident chronic-use vs.
a
b
discontinuing-use
non-users
discontinuing-usec
non-usersd
Baseline age
65-74
Ref.
75-84
1.13 (0.80, 1.59)
85+
2.10 (1.34, 3.28)
-
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Female vs. male
Race
White
Black
Other
Type of Residence
Private
Independent group

-

1.71 (1.22, 2.40)

-

1.27 (1.04, 1.56)

-

Ref.
1.97 (1.34, 2.91)
0.54 (0.17, 1.73)

-

-

Ref.
2.20 (1.00, 4.85)

Ref.
1.68 (1.06, 2.65)

-

Ref.
1.90 (1.43, 2.53)

Care facility

3.14 (0.83, 11.91)

3.46 (1.73, 6.94)

-

2.37 (1.44, 3.90)

Unknown

6.53 (0.77, 55.73)

1.32 (0.60, 2.87)

-

0.67 (0.33, 1.36)

0.45 (0.25, 0.80)
-

2.34 (1.31, 4.16)
0.39 (0.23, 0.65)

0.44 (0.20, 1.00)
-

1.68 (1.09, 2.60)
1.49 (1.21, 1.83)
1.45 (1.14, 1.84)
0.73 (0.55, 0.97)

-

Ref.
2.59 (0.79, 8.45)
4.89 (1.53, 15.65)
1.89 (1.36, 2.63)

Ref.
0.12 (0.02, 0.95)
0.07 (0.01, 0.52)
-

Ref.
0.46 (0.32, 0.65)
0.59 (0.42, 0.83)
1.55 (1.24, 1.93)

Current smoking
Alcohol abuse
Hypertension
Urinary incontinence
Dementia
Number of medications
None
1 to 4
5 or more
Antidepressant agent

Table 2.4. (continued)
Anxiolytic, sedative, or
2.51 (1.76, 3.57)
0.53 (0.31, 0.90)
hypnotic agent
NSAID
1.68 (1.01, 2.78)
Note: Where the reference category is not specified, the comparison is either yes vs. no or ever vs. never. a=Number of
observations used in the model is 290 (prevalent chronic-user: 178 and discontinuing-user: 112); b=Number of observations used
in the model is 12,131 (prevalent chronic-user: 178 and minimal-users: 11,953); c= Number of observations used in the model
is 545 (incident chronic-user: 433 and discontinuing-user: 112); d= Number of observations used in the model is 12,386 (incident
chronic-user: 433 and minimal-users: 11,953)
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Figure 2.1. Sample selection flowchart
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Figure 2.2. Estimated group-based trajectories for any opioid and strong opioid use in
National Alzheimer’s Coordinating Center (NACC) participants (2005-2017)

30

CHAPTER 3. COMPARING THE PATTERNS AND PREDICTORS OF OPIOID USE
IN OLDER ADULTS WITH DIFFERENT COGNITIVE STATUS
Abstract
Background: Older adults with cognitive impairment are more vulnerable due to inherent
difficulties in assessing and treating pain properly. It is important to understand the
potential difference of patterns and predictors of opioid use by cognitive status to provide
detailed guidance to treat pain in the older adults.
Objectives: To evaluate patterns and predictors of opioid use in older adults with different
levels of cognitive function (i.e., normal cognition, mildly impaired cognition, and
dementia).
Methods: Data were extracted from the National Alzheimer’s Coordinating Center
(NACC) Uniform Data Set (2005-2017). We examined opioid use among participants age
65+ with different cognitive status using group-based trajectory modeling. Follow-up was
censored when the participant experienced a change in cognitive status or at the end of the
study period. Among the trajectories, clinical perspective was considered to select the
trajectories to identify the potential predictors (demographics and comorbidities) using
multivariable logistic regression with backward selection.
Results: Among 8,471 participants, 4,595 had normal cognition (mean follow-up [standard
deviation]: 5.5 [2.3]), 1,727 had mildly impaired cognition (4.2 [1.5]), and 2,149 had
dementia (4.3 [1.5]) at enrollment in NACC. For normal cognition, four distinctive
trajectories––minimal-users, incident chronic-users, discontinuing-users and prevalent
chronic-users––were identified with a majority of participants in the minimal-users
(88.4%). For the participants with mildly impaired cognition and patients with dementia,
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three trajectories––minimal-users, incident chronic-user, and prevalent chronic-users––
were identified with a majority of participants in the minimal-users (mildly impaired
cognition: 82.5%; dementia: 91.9%). For participants with normal cognition, race black vs.
white (adjusted odds ratio: 1.90 [95% confidence interval:1.36, 2.66]), type of residence
(independent group vs. private: 1.81 [1.25, 2.61]), year of education (0.91 [0.88, 0.95]),
having urinary incontinence (1.59 [1.11, 2.27]), polypharmacy (1.53 [1.15, 2.04]), and
taking antidepressant agent (1.65 [1.16, 2.35]) were significant predictors of incident
chronic-users vs. minimal-users, whereas having cardiovascular disease (1.63 [1.03, 2.60])
and urinary incontinence (2.30 [1.46, 3.64]) were significant predictors for patients with
dementia.
Conclusions: Given that the patterns and predictors of using opioids varied across the
cognitive status, further studies are needed to estimate whether the different patterns and
predictors are associated with inappropriate use of opioids in older adults.
3.1

Introduction
In the US, CDC reported that one in nine people aged 45 years and older

experienced subjective cognitive decline (SCD), which is an early-stage dementia
condition, and 14.3% reported SCD among people aged 75 years and older from 2015 to
2016 [56]. The prevalence of pain in people with dementia was 30-80% [47, 52]. It is
challenging to treat pain in older adults due to the high rate of polypharmacy and the high
potential of adverse events [17, 47]. It is even more challenging to assess and treat pain in
people with dementia due to their lack of verbal communication [47, 52]. The guidelines
provided by CDC recommend discussing with the caregiver to co-manage the opioid
therapy for older adults with cognitive limitations; however, detailed guidance is lack due
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to the lack of evidence-based studies [31]. Our previous study indicated that having
dementia was negatively associated with chronic-use vs. non-use for opioids [57]. Undertreating pain in older adults could result in serious problems (e.g., aggression, agitation,
confusion, and depression) [47, 52, 53]. Given concern about the serious problems results
from opioid misuse in patients with dementia [47, 52, 53], understanding the potential
differences of patterns and predictors of opioid use by cognitive status, which have not yet
been well studied, can help prevent inappropriate use of opioids and provide different
guidance depending on the older adults cognitive status. Therefore, the objective of this
study is to compare the patterns and predictors of opioids use in older adults with normal
cognition, mildly impaired cognition, and dementia.
3.2

Methods
Study participants
The National Alzheimer’s Coordinating Center’s (NACC) Uniform Data Set

(UDS) funded by National Institute on Aging collects data from Alzheimer’s Disease
Centers (ADC) throughout the US. Local ADCs recruit participants through clinician
referral, self-referral by patients or family members, active community recruitment, and
volunteers with cognitive status ranging from normal to dementia. The participants or coparticipants annually report sociodemographic characteristics, family history, medical
history, neurological evaluations, and medication information [32-34]. This study used
data collected from 38 ADCs between September 2005 and the September 2017 UDS data
freeze. We included participants enrolled at the ADCs between 2005 and 2015 who were
65 years or older and had medication data recorded at every UDS visit. Participants’
cognitive status was assessed at the initial visit using clinician diagnosis and clinician
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dementia rating (CDR) global score: no impairment (CDR=0), questionable impairment
(CDR=0.5), mild impairment (CDR=1), moderate impairment (CDR=2), and severe
impairment (CDR=3). Participants with normal cognition were defined as clinician
diagnosis of normal and CDR global score less than one, participants with mildly impaired
cognition were defined as clinician diagnosis of impaired-not-MCI or mildly cognitive
impaired and CDR global score one or less, and participants with dementia were defined
as clinician diagnosis of dementia and CDR global score one or greater (Figure 3.1).
Participants with discordant cognitive status between clinician diagnosis and CDR global
score (e.g., clinician diagnosis of normal and CDR global score one or more and clinician
diagnosis of dementia and CDR global score 0.5 or less) in the initial visit were excluded.
Also, participants with fewer than three visits were excluded to allow assessing trajectory
trends with quadratic components, and participants with cancer history were excluded due
to the high prevalence of opioid medication. The participants characteristics of who were
included vs. excluded for having fewer than three visits were compared to check possible
selection bias (Table 3.1s).
Opioid use assessment
The participant and/or the caregiver/legally authorized representative reported the
medication use within two weeks of each study visit. The full list of any opioids included
in this study is provided in the supplementary (Table 3.2s). We excluded opioids used as
antitussives.
Participants characteristics
The participant’s characteristics were assessed at the participant’s initial UDS visit.
Demographic information included sex, age, race, type of residence, and years of
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education. Self-reported medical history included alcohol or other substances abuse,
diabetes, cardiovascular conditions, hypertension, smoking status in the last 30 days
(current smoking), and urinary incontinence. Medication information included indicators
of polypharmacy (five or more reported medications, excluding the number of opioid use),
or use of antidepressant, antipsychotic, anxiolytic, sedative, or hypnotic, and nonsteroidal
anti-inflammatory (NSAID) medications.
Statistical analysis
Baseline characteristics for the population included in the study, as well as by
different cognitive status were assessed using descriptive statistics. We used Pearson Chisquare test and One-Way ANOVA to compare the group proportions and means
respectively in different cognitive status.
Group-based trajectory models (GBTM) were used to identify participants with
similar patterns of opioid use during the follow-up time. The maximum follow-up time for
each participant was 12 visits, but the follow-up was truncated when more than 95% of
participants did not have data available for a particular visit [57]. To allow for evaluation
of opioid use trajectories for different groups based on cognitive status, follow-up was also
censored when the participant’s cognitive status changed from the initial visit during the
follow-up. The optimal final models for different cognitive status were determined
considering different numbers and shapes (polynomial terms) of trajectories by the least
negative value of Bayesian Information Criterion (BIC) [40, 41]. The numbers and the
shapes of trajectories indicate how many different patterns of using opioid is in the
population and how do the patterns change over time, respectively. Also, the adequacy of
the final model was confirmed by calculating the average posterior probability of
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membership in the assigned group, which was suggested by Nagin to be greater than 0.7
[40, 41]. In our previous study [57], four trajectories (minimal-users: no use or sporadic
use of opioids during the follow-up ; incident chronic-users: no report of opioid use at their
initial visit, but initiated use during follow-up and consistently reported use during followup; discontinuing-users: used opioids at the initial visit but discontinued during the follow
up; prevalent chronic-users: consistently used opioid during their follow-up visits) were
identified for the older adults enrolled in NACC. For the current study, we defined the
trajectories based on the four trajectories from the previous study.
Considering the clinical perspective on prescribing purposes of opioids, cognitive
status stratified multivariable logistic regressions with backward selections were used to
identify the potential predictors significantly associated with incident chronic-users vs.
minimal-users and prevalent chronic-users vs. discontinuing-users. Adjusted odds ratios
(ORadj) with 95% confidence interval (CI) were obtained from the full and reduced models.
All data analyses were conducted using SAS 9.4®, and 0.05 was set as the significance
level. PROC TRAJ [38] was used to estimate GBTM, and PROC LOGISTIC was used to
fit the logistic regression models.
3.3

Results
A total of 8,471 participants (normal cognition: 4,595; mildly impaired cognition:

1,727; dementia: 2,149) were included in our final sample after applying the inclusion and
exclusion criteria (Figure 3.1). The mean (SD) numbers of follow-up visits was longer in
the normal cognition group (5.5 (2.3) years (range 3 to 10)) than in MCI group (4.2 (1.5)
years (range 3 to 8), p-value: <0.001) and in the dementia group (4.3 (1.5) years (range 3
to 8), p-value: <0.001). The majority of participants were white (normal cognition: 82.1%;
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mildly impaired cognition: 80.1%; dementia: 82.8%). While participants with normal
cognition (67.2%) and dementia (53.2%) groups were majority female, half (50.0%) of
those included in the mildly impaired cognition group were female. The prevalence of
hypertension was the most common comorbidity for all three cognitive status. The use of
antidepressant agents was significantly higher in patients with dementia (38.4%) than in
participants with normal cognition (14.6%). At the initial visit, 3.9%, 4.8%, and 2.9% of
participants with normal cognition, mildly impaired cognition, and dementia, respectively,
reported using any opioids (Table 3.1).
For participants with normal cognition, four trajectories––minimal users (88.4%),
incident chronic-users (6.6%), discontinuing-users (2.6%), and prevalent chronic-users
(2.4%) were identified for any opioid use (Figure 3.2). The definitions for each trajectory
term are above in the methods section. The shapes of the trajectories were all quadratic
except for prevalent chronic-users (cubic) with significant parameter estimate in the
trajectory of incident chronic-users (Table 3.2). For participants with mildly impaired
cognition, three trajectories—minimal-users (82.5%), incident chronic-users (13.6%), and
prevalent chronic-users (3.8%)—were identified for opioid use. (Figure 3.2). The shapes
of the trajectories were all linear with significant parameter estimates in the trajectory of
incident chronic-users and prevalent chronic-users (Table 3.2). For participants with
dementia, three trajectories—minimal users (91.9%), incident chronic-users (4.8%), and
prevalent chronic-users (3.3%)—were identified for any opioid use (Figure 3.2). The
shapes of the trajectories were all quadratic, and the parameter estimate for quadratic
function were significant in minimal-users (Table 3.2). The average posterior probabilities
of all trajectories were confirmed to be at least 0.70 (Table 3.2).
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The predictors of incident chronic-use trajectory membership compared to
minimal-use were identified using multivariable logistic regression models. The full
models and reduced models are presented in Table 3.3. After backward selection, race (
black vs. white (1.90 [1.36, 2.66]), type of residence (independent group vs. private: 1.81
[1.25, 2.61]), year of education (0.91 [0.88, 0.95]), having urinary incontinence (1.59 [1.11,
2.27]), polypharmacy (1.53[1.15, 2.04]), and taking antidepressant agent (1.65 [1.16,
2.35]) were significantly associated with incident chronic-use vs. minimal-use for
participants with normal cognition. For participants with mildly impaired cognition, female
sex 1.56 [1.06, 2.30]), having hypertension (2.24 [1.47, 3.42]), alcohol or other substance
abuse (2.09 [1.08, 4.05]), and taking antidepressant agent (1.56 [1.05, 2.32]) were
significantly associated with incident chronic-use vs. minimal-use. For participants with
dementia, having cardiovascular disease (1.63 [1.03, 2.60]) and urinary incontinence (2.30
[1.46, 3.64]) were significantly associated with incident chronic-use vs. minimal-use
(Table 3.3).
None of the variables included in this study were significant predictors of prevalent
chronic-use vs. discontinuing-use in participants with normal cognition.
3.4

Discussion
This study compared the patterns of any opioid use and the predictors of incident

chronic-use vs. minimal-use of opioids in older adults with different cognitive status. Four
trajectories–– minimal-use, incident chronic-use, discontinuing-use, and prevalent chronicuse––of using opioids were identified for the participants with normal cognition; whereas,
for the participants with mildly impaired cognition and dementia, there were three
trajectories of using any opioids––minimal-use, incident chronic-use, and prevalent
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chronic-use. This result suggests that the patterns of using opioids could be different in the
elderly with cognitive impairment compared to the elderly with normal cognition. Since
participants with mildly impaired cognition are more likely to be monitored by ADC
clinicians, there is a possibility that their probability of initiating opioid use is not high as
participants with normal cognition and dementia.
The prevalence of opioid use at the initial visit was lower in participants with dementia
(2.9%) than normal cognition (3.9%) and mildly impaired cognition (4.8%) (p-value: 0.01).
These results were lower than that reported in a previous study using National Health and
Nutritional Examination Survey from 1999 to 2014 (6.5%) [1]. This could be due to the
different definition of identifying opioid use (used of opioids within two weeks of visit vs.
used of opioids in the past 30 days of interview). The prevalence of opioids in patients with
dementia was consistent with previous study from Finland that found that the overall use
of opioid analgesics was lower in persons with Alzheimer’s disease (AD) (3.6%) compared
to the persons without AD (4.6%) [24]. Having lower prevalence of opioids in participants
with dementia than other older adults could be due to the difficulties in assessing pain in
patients with dementia [18]. However, Bell et al. also reported that the prevalence of strong
opioid use was higher in persons with AD compared to the person without AD (ORadj=1.26;
95% CI=1.05, 1.51) [24]. Also, a register-based cross-sectional study from Denmark has
shown that the prevalence of opioid use was higher in the elderly with dementia compared
to the elderly without dementia [58]. The use of opioids in Danish registers with dementia
has been increased from 2000 to 2015, and this increase was driven by the rise of strong
opioid use in this population [59]. Therefore, further studies are needed to investigate the
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prevalence of opioid use in the elderly with dementia stratified by different strengths of
opioids in the US.
Having urinary incontinence was positively associated with incident chronic-use vs.
minimal-use of opioids for normal cognition and dementia. It has been known that pain
treatment with opioids results in urinary incontinence by decreasing the sensation of
bladder fullness and increase the resistance to the urine flow [60, 61]. Since urinary
incontinence is prevalent in older adults, especially people with dementia [62], future
studies are required to address the risk and benefit of using opioids in this population.
However, this study showed that having polypharmacy was positively associated with
incident chronic-use vs. minimal-use in participants with normal cognition, whereas the
previous study has shown that having polypharmacy was negatively associated with
incident use vs. minimal use in older adults [57]. This result indicates that polypharmacy
could be associated differently with incident chronic-users vs. minimal-users when the
participants have different cognitive status.
To our knowledge, there are limited studies that have investigated the factors associated
with opioid use in persons with dementia. A cross-sectional study involving nursing home
residents in Norway has found that pain, the total number of pain-related diagnoses, and
depression and anxiety were positively associated with strong opioid use in older persons
with advanced dementia [63]. A study from Finland including community-dwelling
persons newly diagnosed with Alzheimer’s disease reported that female sex, older age (
80 years old), having rheumatoid arthritis, history of long-term benzodiazepines and related
drugs were the factors associated with long-term opioid use in persons with Alzheimer’s
disease [24]. Since these studies have different settings (e.g., study population, nursing
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home setting, community-dwelling setting, and list of drugs included in opioid), it is still
difficult to conclude the factors associated with opioid use in patients with dementia.
Therefore, more evidence-based studies are required to thoroughly address the predictors
of using opioids in persons with dementia in the US.
We found that none of the variables of interest that was included in this study was
significantly associated with prevalent chronic-use vs. discontinuing-use for normal
cognition. This result is consistent to the results that we had in the previous study [57].
Future studies are needed to examine the difference of prevalent chronic-use vs.
discontinuing-use including other factors, such as patient’s expectation of long-term opioid
use [30] and the characteristics of physicians [55].
This study has several strengths and limitations. To our knowledge, this study is the
first to compare the longitudinal patterns and predictors of opioid use in older adults with
different cognitive status. NACC data is a validated longitudinal data including a large
number of participants with cognitive range of normal to dementia and collected by trained
clinicians and other ADC researchers. However, NACC data has limitation that since the
use of opioids was assessed within two weeks of the UDS visit, we couldn’t investigate the
continuous use of opioids during the whole days of follow-up. Also, the participants in this
study tend to be highly educated; thus, the result could not be representative of the general
older adults. We assessed the cognitive status of the participants in their initial visits and
censored the follow-up when their cognitive status has been changed. As a sensitivity
analysis, GBTM was performed in the sample without censoring when they change their
cognitive status (results not shown). Similar patterns of trajectories were observed in
participants with normal cognition and mildly impaired cognition. However, for the
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patients with dementia, three trajectories––minimal-users, incident chronic-users, and
discontinuing-use––were identified. Further study could identify the patterns of using
opioids with a time-varying cognitive status. Also, this study could have a probability of
selection bias because we excluded the participants with fewer than three visits and who
did not record medication use. Since the participants who were excluded due to having
fewer than three visits from the study tend to have higher rates of comorbidities and
medication uses (Table 3.1s), the opioid use could be underestimated in our study. The
participants with cognitive impairment and dementia were identified at the enrollment, but
this do not mean that they were newly diagnosed as having cognitive impairment and
dementia at the enrollment. Therefore, further study is needed to investigate the patterns
and predictors of opioid use in newly diagnosed participants with cognitive impairment
and dementia.
In conclusion, the present study investigated that the patterns and predictors of opioid
use varied across the cognitive status, and initiating opioid use was more prevalent among
participants with multiple comorbidities and medications. Further studies are required
whether different patterns and predictors of any opioid use in different cognitive status are
associated with inappropriate use.
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Table 3.1. Baseline characteristics at the initial visit
Total (N=8,471)

Normal Cognition
(N=4,595)

Mildly Impaired
Cognition
(N=1,727)

Dementia
(N=2,149)

p-value

Baseline age
65-74

3,971 (46.9)

2,454 (53.4)

814 (47.1)

703 (32.7)

<0.0001

75-84

3,466 (40.9)

1,623 (35.3)

763 (44.2)

1,080 (44.3)

85+

1,034 (12.2)

518 (11.3)

150 (8.7)

366 (17.0)

Female

5,096 (60.2)

3,089 (67.2)

863 (50.0)

1,144 (53.2)

<0.0001

White

6,920 (81.8)

3,764 (82.1)

1,381 (80.1)

1,775 (82.8)

<0.0001

Black

1,196 (14.1)

707 (15.4)

257 (14.9)

232 (10.8)

Othera

340 (4.0)

116 (2.5)

86 (5.0)

138 (6.4)

15.1 (3.5)

15.6 (3.0)

15.2 (3.5)

14.0 (4.1)

<0.0001

7,316 (86.4)

3,993 (86.9)

1,499 (86.8)

1,824 (84.9)

<0.0001

Independent groupc

686 (8.1)

482 (10.5)

105 (6.1)

99 (4.6)

Care facilityd

223 (2.6)

20 (0.4)

23 (1.3)

180 (8.4)

Unknown

246 (2.9)

100 (2.2)

100 (5.8)

46 (2.1)

304 (3.6)

160 (3.5)

70 (4.1)

74 (3.5)

Race
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Education, mean (SD)
Type of Residence
Privateb

Current smoking

0.51

Table 3.1. (continued)
Ever Alcohol or other

394 (4.7)

138 (3.0)

100 (5.8)

156 (7.3)

<0.0001

Ever hypertension

4,679 (55.4)

2,455 (53.5)

1,014 (58.9)

1,210 (56.5)

0.0004

Ever diabetes

1,090 (12.9)

531 (11.6)

274 (15.9)

285 (13.3)

<0.0001

2,072 (24.7)

996 (21.8)

486 (28.5)

590 (27.7)

<0.0001

Ever urinary incontinence

1,379 (16.3)

557 (12.1)

263 (15.3)

559 (26.1)

<0.0001

Polypharmacye

4,618 (54.5)

2,240 (48.8)

1,001 (58.0)

1,377 (64.1)

<0.0001

Antidepressant agent

1,920 (22.7)

671 (14.6)

424 (24.6)

825 (38.4)

<0.0001

Antipsychotic agent

266 (3.1)

17 (0.4)

33 (1.9)

216 (10.1)

<0.0001

860 (10.2)

455 (9.9)

202 (11.7)

203 (9.5)

0.05

2,848 (33.6)

1,553 (33.8)

632 (36.6)

663 (30.9)

0.0008

321 (3.8)

177 (3.9)

82 (4.8)

62 (2.9)

0.01

substance abuse

Ever cardiovascular
disease
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Anxiolytic, sedative, or
hypnotic agent
NSAID use
Any opioid use

(All results presented are N (%) unless otherwise noted)
Abbreviations: SD, standard deviation; NSAID, nonsteroidal anti-inflammatory medication
Note: a=American Indian, Alaska Native, Native Hawaiian, Other Pacific Islander, Asian, or Other; b=single-or multiple family
private living; c=retirement community, or independent group living; d=assisted living, nursing home, or hospital; e=total
number of medications 5 or more (number of opioids was excluded from the total number of medications)

Table 3.2. Description of estimated trajectories and number of participants in each
trajectory
Average
Trajectory
Estimates
p-valuec
posterior
Group
N
Polynomiala
(SE)b
probabilityd
Normal cognition
Minimal-use

Discontinuing use
Incident chronicuse
Prevalent chronicuse

4,172

Quadratic

89

Quadratic

225

Quadratic

109

Cubic

0.02337
(0.0116)
-0.02904
(0.0414)
-0.06492
(0.0153)
-0.00874
(0.0129)

0.16

0.97

0.48

0.80

<0.001

0.73

0.50

0.75

0.99

0.92

0.03

0.84

0.04

0.82

0.16

0.98

0.01

0.71

0.15

0.89

Mildly impaired cognition
Minimal-use
Incident chronicuse
Prevalent chronicuse

1,537

Linear

124

Linear

66

Linear

2,009

Quadratic

81

Quadratic

59

Quadratic

-16.91784
(2495.33)
0.14466
(0.06574)
0.34492
(0.16739)

Dementia
Minimal-use
Incident chronicuse
Prevalent chronicuse

0.05212
(0.037)
-0.24815
(0.096)
-0.07829
(0.054)

Note: a=highest order of the trajectory group; b=parameter estimates of the highest order
and standard error (SE); c=p-value for the highest order of the trajectory group; d=average
posterior probability for the participants assigned to the trajectory group
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Table 3.3. Predictors associated with incident chronic-use vs. minimal-use of any opioid in multivariable logistic regression
model
Normal cognition
Mildly impaired cognition
Dementia
Reduced
Reduced
Reduced
Full Model
Full Model
Full Model
Model
Model
Model
Baseline age
65-74
Ref.
Ref.
Ref.
1.08
1.29
1.07
75-84
(0.79, 1.48)
(0.86, 1.93)
(0.63, 1.84)
1.28
0.84
0.94
85+
(0.81, 2.01)
(0.38, 1.85)
(0.46, 1.90)
0.97
1.39
1.56
1.13
Female vs. male
(0.71, 1.33)
(0.92, 2.09)
(1.06, 2.30)
(0.69, 1.87)
Race
White
Ref.
Ref.
Ref.
Ref.
1.88
1.90
1.42
0.85
Black
(1.31, 2.69)
(1.36, 2.66)
(0.86, 2.34)
(0.37, 1,96)
1.03
1.03
0.58
0.78
Othera
(0.41, 2.63)
(0.41, 2.59)
(0.22, 1.56)
(0.26, 2.30)
Education (1-year
0.92
0.91
0.96
1.02
difference)
(0.88, 0.96)
(0.88, 0.95)
(0.91, 1.01)
(0.95, 1.08)
Type of Residence
Privateb
Ref.
Ref.
Ref.
Ref.
Independent
1.61
1.81
1.18
1.11
groupc
(1.08, 2.41)
(1.25, 2.61)
(0.54, 2.61)
(0.39, 3.17)
2.82
2.91
4.15
2.03
Care facilityd
(0.60, 13.34) (0.61, 13.75)
(1.34, 12.85)
(1.06, 3.89)
0.43
0.41
1.16
0.56
Unknown
(0.10, 1.76)
(0.10, 1.69)
(0.55, 2.43)
(0.07, 4.14)

Table 3.3. (continued)
1.26
2.00
2.24
1.08
(0.92, 1.72)
(1.27, 3.14)
(1.47, 3.42)
(0.65, 1.79)
1.14
1.12
1.23
Diabetes
(0.77, 1.69)
(0.68, 1.85)
(0.63, 2.39)
Cardiovascular
1.19
1.16
1.64
1.63
disease
(0.87, 1.64)
(0.76, 1.75)
(1.01, 2.67)
(1.03, 2.60)
Urinary
1.53
1.59
1.11
2.13
2.30
incontinence
(1.07, 2.12)
(1.11, 2.27)
(0.67, 1.83)
(1.31, 3.44)
(1.46, 3.64)
Alcohol or other
0.74
1.89
2.09
0.83
substance abuse
(0.31, 1.75)
(0.95, 3.76)
(1.08, 4.05)
(0.32, 2.17)
0.87
1.17
1.28
Current smoking
(0.41, 1.83)
(0.49, 2.77)
(0.38, 4.30)
1.38
1.53
1.32
0.80
Polypharmacye
(0.99, 1.92)
(1.15, 2.04)
(0.82, 2.11)
(0.47, 1.36)
1.62
1.65
1.34
1.56
1.38
Antidepressant agent
(1.12, 2.35)
(1.16, 2.35)
(0.88, 2.04)
(1.05, 2.32)
(0.85, 2.26)
Anxiolytic, sedative,
1.51
1.67
0.89
or hypnotic agent
(1.00, 2.30)
(0.99, 2.81)
(0.41, 1.95)
1.23
1.97
0.89
Antipsychotic agent
(0.16, 9.68)
(0.66, 5.93)
(0.43, 1.87)
0.94
0.93
0.80
NSAID
(0.68, 1.28)
(0.61, 1.41)
(0.46, 1.40)
Note: Where the reference category is not specified, the comparison is either yes vs. no or ever vs. never
Abbreviations: NSAID, nonsteroidal anti-inflammatory medication
Note: a=American Indian, Alaska Native, Native Hawaiian, Other Pacific Islander, Asian, or Other; b=single-or multiple family
private living; c=retirement community, or independent group living; d=assisted living, nursing home, or hospital; e=total
number of medications 5 or more (number of opioids was excluded from the total number of medications)
Hypertension
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Cognitive status was assessed at the initial visit; CDR: Clinician Dementia Rating
*CDR global score ‐ 0: No impairment; 0.5: questionable impairment; 1: Mild impairment;
2: Moderate impairment; 3: Severe impairment

Figure 3.1. Sample selection flowchart
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Figure 3.2. Estimated group-based trajectories for any opioid use in National Alzheimer’s Coordinating Center (NACC)
participants (2005-2017)
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CHAPTER 4. AN INVESTIGATION OF PREDICTORS OF LONG-TERM OPIOID
USE IN MEDICAID BENEFICIARIES WITH HIV WHO INITIATED
ANTIRETROVIRAL THERAPY
Abstract
Background: Pain management is important for assuring the quality of life in patients with
HIV. However, pain management using opioids may have an inadequate risk/benefit ratio.
Little is known about risk factors associated with long-term opioid use in this population.
Although HIV-infected women report more severe pain and are prescribed more opioids,
sex-specific factors associated with filling long-term opioid has not been investigated.
Objectives: To identify factors predicting long-term opioid use and to examine the sexspecific predictors of long-term opioid use in Medicaid beneficiaries with HIV after
standard combination anti-retroviral therapy (cART) initiation.
Methods: Using Medicaid data (2002-2009) from Kentucky (KY), Maryland (MD), North
Carolina (NC), and Washington (WA), we conducted a retrospective cohort study to
examine long-term opioid use in patients with HIV initiating cART. Long-term opioid use
was defined as 90 days of continuous use, accepting 32 days gap over a six-month period.
We excluded any patients who filled a prescription of ART or long-term opioid during the
washout period defined as the six-months prior to initiating cART. Potential predictors of
long-term opioid use (demographic characteristics, comorbidities, specific medications,
and polypharmacy based on number of medications used, excluding cART) were measured
during the washout period. The significant predictors were identified using generalized
estimating equation (GEE) regression models with backward selection, accounting for
clustering within states, and adjusted odds ratios (ORadj) with 95% confidence intervals
(CI) were estimated.
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Results: Long-term opioid use occurred among 1,014 out of 9,615 (10.5%) eligible
beneficiaries with HIV. The prevalence of long-term opioid use was similar for male and
female beneficiaries with HIV (10.4% and 10.7%, respectively). Strong predictors of longterm opioid use were prior use of any opioids (ORadj=1.86; 95% CI=1.61-2.13),
polypharmacy defined as the use of 5 or more medications (ORadj=1.71; 1.40-2.09), use of
benzodiazepine (1.62; 1.48-1.77), drug abuse diagnosis (1.62; 1.25-2.12), hepatitis C
infection (1.55; 1.47-1.64), and back pain (1.46; 1.10-1.93). Factors associated with lower
odds of long-term opioid use were having psychotic disorder (0.70; 0.62-0.79), any fracture
(0.70; 0.55-0.89), cardiovascular disease (0.77; 0.68-0.88), and black vs. white (0.77; 0.650.91). Many predictors of long-term opioid use were shared between male and female;
however, dementia (0.92; 0.72-1.18), diabetes (0.69; 0.50-0.96), and neuropathy pain
(1.62; 1.38-1.90) were the predictors of long-term opioid use in male, whereas, chronic
obstructive pulmonary disease (1.25; 0.94-1.66), liver disease (0.75; 0.62-0.90), any
malignancy (1.61; 1.25-2.07), and use of antipsychotic (1.19; 1.06-1.35) were predictors
of long-term opioid use in female.
Conclusions: Comorbidities and polypharmacy were important predictors of long-term
opioid use in Medicaid beneficiaries with HIV initiating cART. Further studies should
evaluate patient outcomes associated with prescribing long-term opioids in this population
and fully investigate the sex differences.
4.1

Introduction
The introduction of combination anti-retroviral therapy (cART) has contributed to

the reductions in mortality and morbidity from Human Immunodeficiency Virus (HIV)
infection. Hence, the quality of life and chronic disease related to patients with HIV are an
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emerging research area. Among patients with HIV, 39% to 85% have reported chronic pain
[64, 65], and 50% of patients with HIV filled prescriptions for opioids [66]. They have
reported general pain, such as head, leg, and back pain; neuropathic pain; and Kaposi
sarcoma-related pain [64]. Previous studies showed that the prevalence of high-dose opioid
prescribing is higher in patients with HIV compared to the general population [67, 68], and
the incidence of chronic opioid therapy was reported to be 1.5 times higher in opioid-naïve
people living with HIV compared to those without HIV, after adjusting for demographics
and comorbidities [69]. Pain management is important for patients with HIV, but the
characteristics and the effect of using long-term opioid in patients with HIV are not fully
investigated, yet.
Although one-quarter of patients with HIV in the US are women [70], most of the
observational studies that have examined the association between prescribing opioids and
HIV status have focused on men [67, 68, 71]. However, in descriptive studies, it has been
reported that HIV-infected women suffer from more severe pain [66] and are prescribed
more opioids [72] compared to HIV-infected men. Moreover, a longitudinal study reported
that female gender was positively associated with chronic users compared to
never/sporadic users among patients with HIV [73]. Thus, inclusion of both men and
women is crucial when assessing opioid prescribing and prescription opioid-related health
concerns in patients with HIV, but women are often excluded from such studies.
Therefore, this study aimed to (1) understand the characteristics of patients with
HIV who become long-term opioid users; and (2) investigate the sex-specific factors
associated with long-term opioid use among Medicaid beneficiaries with HIV after
standard cART initiation. Identifying characteristics associated with long-term opioid use
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in patients with HIV will provide factors that could be instrumental in assessing risk and
inappropriate use of opioid in patients with HIV.
4.2

Methods
Data source and study population
Medicaid administrative data (2002-2009), which includes people with low

income, pregnant women, and people with disabilities, obtained from the Centers for
Medicaid and Medicare Services was used for this study. This study included Medicaid
Analytic eXtract (MAX) personal summary file (PS), inpatient (IP), prescription (RX), and
other services (OT) from the four states––Kentucky (KY), Maryland (MD), North Carolina
(NC), and Washington (WA)––with four unique HIV epidemics. We included patients with
HIV defined as those who filled prescriptions for standard combination anti-retroviral
therapy (cART) on the same date (i.e., cohort entry date) for at least seven days’ supply
among Medicaid eligible beneficiaries between 2002 and 2009. Standard cART regimens
included two nucleoside reverse transcriptase inhibitors (NRTIs) with one of nonnucleoside reverse transcriptase inhibitor (NNRTI), integrase strand transfer inhibitor
(INSTI), or protease inhibitor (PI). The drug name and class of ART was identified from
the Medicaid data using national drug codes (NDC) linked with Medispan Generic Product
Identifiers. Inclusion criteria included: (1) 18 and older or less than 65 years of age at the
cohort entry date; (2) continuous eligibility for at least 180 days prior to the cohort entry
date allowing one-month gap (i.e., washout period). We excluded the beneficiaries who (1)
had less than six-months between enrollment and standard cART regimen start date; (2)
filled long-term opioid prescriptions during washout period; (3) had no medical or
prescription claim during washout period. The follow-up time for each participant was until
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the earliest of: (1) loss of Medicaid eligibility for >31 days when multiple enrollment
occurred; (2) end of the study period (December 31, 2009).
Identification of long-term opioid users
Long-term opioid use was defined as at least 90 days of continuous use of opioids
(accepting less than or equal to 32 days of the prescription gap) with multiple opioid
prescription claims in a six months period [74-76]. Opioid drugs were identified using
NDC linked with Medispan Generic Product Identifiers (starting with ‘65’).
Potential predictors
Demographic variables, including age, sex, race, and state, were assessed at the
cohort entry date. Age was calculated at cohort entry date based on beneficiaries’ date of
birth using PS files. International Classification of Disease, 9th Clinical Modification (ICD9-CM) codes were used based on existing validated definition [77-82] listed anywhere in
the IP and OP files to identify beneficiaries’ medical history, and NDCs were used to
identify use of medications. Medical history, including cardiovascular disease,
hypertension, dementia, chronic obstructive pulmonary disease (COPD), liver disease,
diabetes, renal disease, any malignancy (including lymphoma and leukemia, except
malignant neoplasm skin), metastatic solid tumor, alcohol abuse, hepatitis C infection,
depression, psychotic disease, back pain, neck pain, arthritis, migraine, opportunistic
infection, tobacco use disorder, neuropathy pain, unclassified pain, any fracture, and
surgery history, were assessed during the washout period. From the RX file, use of
medications, including any opioid use, benzodiazepine, gabapentinoid, pain medication,
antidepressant, antipsychotic, and polypharmacy, were assessed during the washout period.
When calculating the number of medications for polypharmacy, the number of medications
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for ART was excluded. A detailed description of the variables considered in the analysis is
included in Table 4.1s.
Statistical analysis
Baseline characteristics of the Medicaid beneficiaries included in this analysis were
summarized using mean with standard deviation (SD) for age, median with interquartile
range (IQR) for follow-up days, and frequencies with percentages for categorical variables.
We used t-test and Pearson Chi-Square test to compare the differences between long-term
opioid users and no long-term opioid users. To identify the predictors of long-term opioid
use in HIV-infected beneficiaries who initiated ART, we used Generalized Estimation
Equation (GEE) multivariable logistic regressions, accounting for clustering at the state
level. The final reduced models were selected by manual backward selection using the
lowest Quasi Information Criterion (QIC). Additionally, multivariable logistic regression
models with backward selection and least absolute shrinkage and selection operator
(LASSO) regression with the Schwarz Bayesian Information Criterion (SBC) [83, 84] were
used to confirm the factors associated with long-term opioid users from GEE multivariable
logistic model. When using the LASSO regression, the factors selected by LASSO were
entered into the GEE multivariable logistic regression to account for clustering within
states.
Stratified analyses were used to investigate sex-specific predictors of long-term
opioid use. The GEE multivariable logistic regression with backward selection were used
to identify the factors associated with long-term opioid use by sex.
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Adjusted odds ratios (ORadj) with 95% confidence intervals (CI) were obtained
from the full and reduced models. All data analyses were conducted using SAS 9.4®, and
0.05 was set as the significance level.
4.3

Results
In this study, 9,615 Medicaid beneficiaries (mean (SD) age: 41 (10.2) years) with

HIV were included after applying inclusion and exclusion criteria (Figure 4.1). The median
(IQR) follow-up days for this sample was 783 days (297-1,634) and the majority
beneficiaries was male (53.6%) (Table 4.1). Among the final sample of beneficiaries with
HIV (N=9,615), a total of 1,014 beneficiaries were long-term opioid users. The median
(IQR) follow-up days was longer in long-term opioid users (1,481.5 (864-2,131) days)
compared to no long-term opioid users (694 (264-1,549) days). The long-term opioid users
were older (43.5 years vs. 40.7 years, p-value: <0.0001), of white race (26.1% vs. 19.1%,
p-value: <0.0001), and had more comorbidities during washout period than no long-term
opioid users. The most common comorbidity was arthritis and joint pain (final sample:
20.5%; long-term opioid users: 30.5%; no long-term opioid users: 19.4%). Long-term
opioid users had higher percentage of 5 or more medications (16% vs. 9.4%) compared to
no long-term opioid users, and half of the beneficiaries in the long-term opioid users had a
history of filling at least one opioid prescription during washout period (50.9%), whereas
approximately 30% of no long-term opioid users filled at least one opioid prescription
(Table 4.1).
Predictors of long-term opioid use
GEE multivariable logistic regression models, accounting for clustering at the state
level, were used to identify the predictors of long-term opioid use among beneficiaries with
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HIV. Full model, including all variables listed in the Table 4.1, and the reduced model are
reported in Table 4.2. After backward selection, several factors emerged as positively
significant predictors associated with long-term opioid use among Medicaid beneficiaries
with HIV: demographic characteristic (age), medical history (COPD, any malignancy,
hepatitis C infection, opportunistic infection, drug abuse, back pain, arthritis, neuropathy
pain), and use of medications (pain medication, benzodiazepine, gabapentinoid,
antidepressant, antipsychotic, any opioid, 5+ medication vs. none, 1-4 medications vs.
none). Several factors were negatively associated with long-term opioid use: demographic
characteristic (race: black vs. white and other vs. unknown) and medical history
(cardiovascular disease, diabetes, psychotic disorder, any fracture, alcohol abuse) (Table
4.2).
The reduced model without accounting for clustering within states reported similar
ORadj with 95% CI, but COPD, diabetes, any malignancy, any fracture, opportunistic
infection, alcohol abuse, arthritis, and use of antipsychotic were not included in the reduced
model without clustering (Table 4.2s). Another reduced model using LASSO reported
similar ORadj with 95% CI, but factors, including cardiovascular disease, diabetes, any
malignancy, psychotic disorder, any fracture, opportunistic infection, alcohol abuse,
antipsychotic were not in the reduced model using LASSO (Table 4.2s). After selecting
factors by LASSO, the factors were entered into the GEE multivariable logistic regression.
Thus, considering state as a significant clustering factor in this study, GEE multivariable
logistic regression models were selected as our final model.
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Characteristics of the beneficiaries by sex
Among the total Medicaid beneficiaries with HIV (N=9,615), a total of 5,154
Medicaid beneficiaries were male and 4,460 Medicaid beneficiaries were female. The
mean age (SD) was younger in female (39.0 (10.4)) than male (42.7 (9.6)), and the median
(IQR) follow-up days was longer in female (801 (307.5-1,624)) then male (759 (2871,646)). The most common comorbidity in both sex was arthritis and joint pain (male:
20.2%; female: 20.9%). The male beneficiaries in Medicaid had higher percentage of
taking 5 or more medications (11.1%) than female (8.9%) (Table 4.3).
Among male beneficiaries, the most common comorbidities were arthritis and joint
pain for both long-term opioid users (30.5%) and no long-term opioid users (19%). The
most frequent use of medication was antidepressant for long-term opioid users (35%) and
no long-term opioid users (23%). Almost half of the male beneficiaries with long-term
opioid users (48.6%) filled the prescription of any opioid during washout period. Among
female beneficiaries, the most common comorbidity was drug abuse (33.0%) for long-term
opioid users and arthritis and joint pain (19.8%) for no long-term opioid users. Almost half
of the female long-term opioid users filled the prescription of antidepressant (45.2%),
whereas 27.3 % of female no long-term opioid users filled the prescription of
antidepressant. More than half of the female beneficiaries (53.4%) with long-term opioid
use filled the prescription of opioids during the washout period (Table 4.3).
Predictors of long-term opioid use by sex
The predictors of long-term opioid use (reduced model) in male and female,
accounting for clustering within state, are presented in Figure 4.2. The full models and
reduced models with clustering and without clustering in male and female are presented in
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Table 4.3s. Many factors for long-term opioid use were shared between male and female
(age; race; having cardiovascular disease, hypertension, renal disease, metastatic solid
tumor, hepatitis C infection, psychotic disorder, any fracture, surgery history, drug abuse,
tobacco use disorder, back pain, neck pain, arthritis, and unclassified pain; polypharmacy;
taking pain medication, benzodiazepine, gabapentinoid, antidepressant, and any opioid).
However, dementia (0.92 [0.72, 1.18]), diabetes (0.69 [0.50, 0.96]), and neuropathy pain
(1.62 [1.38, 1.90]) were the factors associated with long-term opioid use in male, whereas,
COPD (1.25 [0.94, 1.66]), liver disease (0.75 [0.62, 0.90]), any malignancy (1.61 [1.25,
2.07]), and use of antipsychotic (1.19 [1.06, 1.35]) were the factors associated with longterm opioid use in female (Figure 4.2).
4.4

Discussion
This study identified potential predictors of long-term opioid use in Medicaid

beneficiaries with HIV. Among patients with HIV, 10.5% Medicaid beneficiaries were
long-term opioid users. The overall prevalence of long-term opioid use in this study was
higher than a study conducted by Canan et al. (4.0%) using Medicaid beneficiaries in 14
states between 2001 and 2009 [69]. This could be due to differences in definition used to
identify new long-term opioid user––allowed any opioid use before long-term opioid use
in our study vs. included only opioid-naïve individuals in Canan et al. study [69]. In this
study, the prevalence of long-term opioid use was similar between male (10.4%) and
female (10.7%). This result is inconsistent to the previous studies that reported that HIVinfected women suffer from more pain [66], and that female sex is the predictor of longterm opioid use in HIV-infected Kaiser Permanente members [72]. This could be due to
the different populations included in the study––Medicaid beneficiaries in KY, MD, WA,
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and NC vs. Kaiser Permanente members in Northern California. However, in our data, the
prevalence of long-term opioid use in WA, which is part of Northern California, was higher
in male (13.3%) than in female (10.2%). Among the four states, only the prevalence of
long-term opioid use in MD (male vs. female: 10.1% vs. 12.1%) was higher in female.
Therefore, further studies are needed to examine the differences of long-term opioid use
by sex in different states. We found that Medicaid recipients with HIV in this study had
similar prevalence of pain-related symptoms (back pain, neck pain, arthritis and joint pain,
and neuropathy pain), except higher prevalence in unclassified pain in female (6.5% vs.
2.4%). Therefore, it is possible that the female Medicaid beneficiaries with HIV have
similar prevalence of pain-related symptoms and long-term opioid use compared to male
Medicaid beneficiaries with HIV due to characteristics (e.g., people with low-income,
pregnant women, and people with disability) of the people included in Medicaid. Further
studies are needed to investigate the prevalence of long-term opioid use in the general
population.
The factors associated with long-term opioid use among Medicaid beneficiaries
with HIV included age; race; having cardiovascular disease, COPD, diabetes, any
malignancy, hepatitis C infection, psychotic disorder, opportunistic infection, alcohol
abuse, drug abuse, back pain, arthritis, and neuropathy pain; use of pain medication,
benzodiazepine, gabapentinoid, antidepressant, antipsychotic, and any opioid; and taking
1 to 4 medications vs. none, and 5 or more medications vs. none, after clustering within
states. These factors were consistent to a study that found that factors, including age 40 to
49 years vs. 18 to 39 years, female sex, Charlson Comorbidity Index score two or more vs
zero, injection of drug use history, depression, and substance use disorders, were associated
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with prevalent long-term opioid use in 2005 using HIV-infected Kaiser Permanente
members [72]. Also, some of the factors associated with long-term opioid use were shared
between this study and a study using older adults enrolled in the National Alzheimer’s
Coordinating Center [57]. Older age, taking antidepressant, anxiolytic, sedative, or
hypnotic agents, polypharmacy were factors associated with long-term opioid use in both
studies [57]. This indicates that more vulnerable patients (i.e., older age, taking
benzodiazepine, and with higher number of medications) were more likely to be long-term
opioid users in vulnerable populations, such as older adults and patients with HIV.
We found that use of benzodiazepine and gabapentinoid were strong predictors of
long-term opioid use in Medicaid beneficiaries with HIV in both sex. The guidelines
provided by CDC in 2016 suggest to avoid using opioids and benzodiazepine concurrently
due to the risk of fatal overdose [13], and recently, the FDA warned about the potential risk
of respiratory depression in patients using opioids and gabapentin concurrently [85].
Therefore, further studies are needed to investigate whether the long-term opioid users in
patients with HIV are concurrently using benzodiazepine or gabapentin and examine the
risk of using these drugs in patients with HIV with long-term opioid use.
Most of the comorbidities were positively associated with long-term opioid use in
patients with HIV, but having psychotic disorder was negatively associated with long-term
opioid use in both sex. In general population, having history of psychotic disorder is one
of the factors positively associated with long-term opioid use [29, 86]. However, this
pattern was not observed in this study with patients with HIV. Since patients with HIV
with psychotic disorders are known to have higher stimulant abuse and mortality rate [87,
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88], there is a possibility that the physicians are careful in prescribing opioid chronically
in patients with HIV.
We found that having diabetes and neuropathy pain were associated with long-term
opioid use in male beneficiaries with HIV but not in female, and having liver disease and
taking antipsychotic medications were associated with long-term opioid use in female
beneficiaries with HIV but not in male. There is little study done in the sex differences of
predictors of long-term opioid users in patients with HIV; thus, further studies are needed
to fully understand how the predictors have different effect on long-term opioid use by sex.
There are several strengths and limitations in this study. The majority of people
included in the previous studies was male [67, 71, 89]; however, this study included 46.4%
of female which allowed us to assess the long-term opioid use in both sex. We have several
unmeasured potential predictors (e.g., clinician characteristic, family history of opioid use,
and use of over the counter drugs) due to the limitation of claims data. We used
opportunistic infection to measure the severity of HIV disease; however, the accurate
severity of HIV disease (CD4 cell count) could not be included in this study. Finally, since
this study used Medicaid data with four states, the results may not be generalized to the
overall patients with HIV.
In conclusion, long-term opioid use is prevalent in Medicaid beneficiaries with
HIV, and having comorbidities, taking medications, and polypharmacy were significant
predictors of long-term opioid use in this population. We found that while many predictors
of long-term opioid use were shared between male and female, having diabetes and
neuropathy pain were male-specific predictors and taking antipsychotic and having liver
disease were female-specific predictors. These sex-specific predictors should be fully
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investigated when assessing the risk and benefit of using long-term opioid in patients with
HIV. Also, further studies should investigate the patients’ outcomes associated with
prescribing long-term opioids in patients with HIV.
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Table 4.1. Characteristics of Study Sample
Total
(N=9,615)

Long-term

No long-term

opioid users

opioid users

(N=1,014)

(N=8,601)

p-value

Age, mean (SD)

41.0 (10.2)

43.5 (7.6)

40.7 (10.4)

<0.0001

Female

4460 (46.4)

476 (47.0)

3986 (46.3)

0.69

White

1911 (19.9)

265 (26.1)

1646 (19.1)

<0.0001

Black

7057 (73.4)

686 (67.7)

6371 (74.1)

Other*

266 (2.8)

23 (2.3)

243 (2.8)

Unknown

381 (4.0)

40 (3.9)

341 (4.0)

Kentucky

407 (4.2)

40 (3.9)

367 (4.3)

Maryland

4573 (47.6)

508 (50.1)

4065 (47.3)

North Carolina

3589 (37.3)

334 (32.9)

3255 (37.8)

Washington

1046 (10.9)

132 (13.0)

914 (10.6)

913 (9.5)

111 (11.0)

802 (9.3)

0.10

1727 (18.0)

236 (23.3)

1491 (17.3)

<0.0001

161 (1.7)

21 (2.1)

140 (1.6)

0.30

COPD

1332 (13.9)

192 (18.9)

1140 (13.3)

<0.0001

Any liver disease

995 (10.4)

161 (15.9)

834 (9.7)

<0.0001

Diabetes

695 (10.4)

89 (8.8)

606 (7.1)

0.04

Renal disease

536 (5.6)

65 (6.4)

471 (5.5)

0.22

Any malignancy

377 (3.9)

59 (5.8)

318 (3.7)

0.001

Metastatic solid tumor

59 (0.6)

12 (1.2)

47 (0.6)

0.014

Hepatitis C infection

1069 (11.1)

196 (19.3)

873 (10.2)

<0.0001

Depression

1750 (18.2)

239 (23.6)

1511 (17.6)

<0.0001

Psychotic disorder

626 (6.5)

69 (6.8)

557 (6.5)

0.69

Migraine/headache

123 (1.3)

14 (1.4)

109 (1.3)

0.76

Any fracture

209 (2.2)

25 (2.5)

184 (2.1)

0.50

Race

State

Cardiovascular
disease
Hypertension
Dementia
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0.006

Table 4.1. (continued)
Surgery history

105 (1.1)

13 (1.3)

92 (1.1)

0.54

1863 (19.4)

234 (23.1)

1629 (18.9)

0.002

814 (8.5)

104 (10.3)

710 (8.3)

0.03

1850 (19.2)

302 (29.8)

1548 (18.0)

<0.0001

834 (8.7)

109 (10.8)

725 (8.4)

0.013

Back pain

790 (8.2)

153 (15.1)

637 (7.4)

<0.0001

Neck pain

277 (2.9)

45 (4.4)

232 (2.7)

0.002

1973 (20.5)

309 (30.5)

1664 (19.4)

<0.0001

Neuropathy pain

938 (9.8)

163 (16.1)

775 (9.0)

<0.0001

Unclassified pain

413 (4.3)

62 (6.1)

351 (4.1)

0.003

None

3536 (36.8)

289 (28.5)

3247 (37.8)

<0.0001

1-4

5113 (53.2)

563 (55.5)

4550 (52.9)

5+

966 (10.1)

162 (16.0)

804 (9.4)

Pain medication

2284 (23.8)

336 (33.1)

1948 (22.7)

<0.0001

Benzodiazepine

940 (9.8)

191 (18.8)

749 (8.7)

<0.0001

Gabapentinoid

576 (6.0)

114 (11.2)

462 (5.4)

<0.0001

Antidepressant

2550 (26.5)

403 (39.7)

2147 (25.0)

<0.0001

Antipsychotics

1242 (12.9)

180 (17.8)

1062 (12.4)

<0.0001

Any opioid use

3050 (31.7)

516 (50.9)

2534 (29.5)

<0.0001

Opportunistic
infection
Alcohol abuse
Drug abuse
Tobacco use disorder
Pain-related disorder

Arthritis/joint pain

Number of
medications

Abbreviation: COPD, Chronic pulmonary disease
All results presented are N (%) unless otherwise noted
*American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian,
more than one race
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Table 4.2. Predictors of long-term opioid use vs. no long-term opioid use in Medicaid
beneficiaries with HIV
Full Model
Reduced Model
ORadj (95% CI)

ORadj (95% CI)

Age

1.02 (1.01 1.03)

1.02 (1.01, 1.03)

Female

1.06 (0.82, 1.37)

Race
Black vs. white

0.76 (0.62, 0.93)

0.77 (0.65, 0.91)

Other* vs. white

0.67 (0.58, 0.79)

0.68 (0.59, 0.78)

Unknown vs. white

0.82 (0.67, 1.01)

0.84 (0.67, 1.05)

Cardiovascular disease

0.78 (0.64, 0.96)

0.77 (0.68, 0.88)

HTN

1.11 (0.95, 1.30)

Dementia

0.89 (0.58, 1.36)

COPD

1.16 (0.90, 1.50)

Liver

0.93 (0.74, 1.16)

Diabetes

0.91 (0.78, 1.05)

Renal disease

0.85 (0.58, 1.25)

Any malignancy

1.26 (1.18, 1.35)

Metastatic solid tumor

1.10 (0.67, 1.83)

Hepatitis C infection

1.62 (1.41, 1.87)

Depression

0.98 (0.75, 1.30)

Psychotic disorder

0.71 (0.63, 0.80)

Migraine/headache

0.86 (0.61, 1.21)

Any fracture

0.70 (0.57, 0.87)

Surgery history

1.04 (0.77, 1.39)

Opportunistic infection

1.05 (0.98, 1.13)

1.04 (0.98, 1.11)

Alcohol abuse

0.85 (0.69, 1.03)

0.84 (0.66, 1.05)

Drug abuse

1.62 (1.22, 2.16)

1.62 (1.25, 2.12)

Tobacco use disorder

0.86 (0.74, 1.00)

Back pain

1.44 (1.11, 1.88)

Neck pain

1.02 (0.88, 1.17)
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1.18 (0.92, 1.51)

0.92 (0.82, 1.02)

1.28 (1.23, 1.33)

1.55 (1.47, 1.64)

0.70 (0.62, 0.79)

0.70 (0.55, 0.89)

1.46 (1.10, 1.93)

Table 4.2. (continued)
Arthritis

1.11 (0.98, 1.26)

1.13 (1.01, 1.25)

Neuropathy pain

1.18 (1.04, 1.33)

1.17 (1.05, 1.30)

Unclassified pain

1.04 (0.91, 1.20)

Number of medications
5+ medications vs. none

1.35 (1.29, 1.41)

1.34 (1.29, 1.40)

1-4 medications vs. none

1.73 (1.44, 2.08)

1.71 (1.40, 2.09)

Pain medication

1.15 (0.94, 1.41)

1.16 (0.96, 1.40)

Benzodiazepine

1.62 (1.49, 1.76)

1.62 (1.48, 1.77)

Gabapentinoid

1.33 (1.21, 1.46)

1.33 (1.21, 1.45)

Antidepressant

1.31 (1.06, 1.62)

1.31 (1.10, 1.56)

Antipsychotic

1.09 (0.96, 1.24)

1.09 (0.99, 1.21)

Any opioid use

1.85 (1.59, 2.15)

1.86 (1.61, 2.13)

* American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian,
more than one race
Note: Generalized estimate equation multivariable logistic regressions, accounting for
clustering at the state level, were used and the reduced model was selected by backward
selection
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Table 4.3. Characteristics of study sample by sex
Male (N=5,154)

Female (N=4,460)

Long-term

Not long-term

Long-term

Not long-term

opioid users

opioid users

opioid users

opioid users

(N=537)

(N=4,617)

(N=476)

(N=3,984)

42.7 (9.6)

44.3 (7.3)

42.5 (9.9)

39.0 (10.4)

42.5 (7.8)

38.6 (10.6)

White

1,264 (24.5)

162 (30.2)

1,102 (23.9)

646 (14.5)

102 (21.4)

544 (16.7)

Black

3,517 (68.2)

338 (62.9)

3,179 (68.9)

3,540 (79.4)

348 (73.1)

3,192 (80.1)

Other*

141 (2.7)

15 (2.8)

126 (2.7)

125 (2.8)

8 (1.7)

117 (2.9)

Unknown

232 (4.5)

22 (4.1)

210 (4.6)

149 (3.3)

18 (3.8)

131 (3.3)

Kentucky

226 (4.4)

28 (5.2)

198 (4.3)

181 (4.1)

12 (2.5)

169 (4.2)

Maryland

2,300 (44.6)

232 (43.2)

2,068 (44.8)

2,273 (51.0)

276 (58.0)

1,997 (50.1)

North Carolina

1,839 (35.7)

172 (32.0)

1,667 (36.1)

1,750 (39.2)

162 (34.0)

1,588 (39.9)

789 (15.3)

105 (19.6)

684 (14.8)

256 (5.7)

26 (5.5)

230 (5.8)

525 (10.2)

61 (11.4)

464 (10.1)

388 (8.7)

50 (10.5)

338 (8.5)

Hypertension

882 (17.1)

113 (21.0)

769 (16.7)

845 (19.0)

123 (25.8)

722 (18.1)

Dementia

104 (2.0)

14 (2.6)

90 (2.0)

57 (1.3)

7 (1.5)

50 (1.3)

Total
(N=5,154)
Age, mean (SD)

Total
(N=4,460)

Race
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State

Washington
Cardiovascular
disease

Table 4.3. (continued)

Chronic pulmonary

583 (11.3)

76 (14.2)

507 (11.0)

749 (16.8)

116 (24.4)

633 (15.9)

Any liver disease

580 (11.3)

91 (17.0)

489 (10.6)

415 (9.3)

70 (14.7)

345 (8.7)

Diabetes

366 (7.1)

38 (7.1)

328 (7.1)

329 (7.4)

51 (10.7)

278 (7.0)

Renal disease

336 (6.5)

41 (7.6)

298 (6.4)

200 (4.5)

24 (5.0)

176 (4.4)

Any malignancy

234 (4.5)

31 (5.8)

203 (4.4)

143 (3.2)

28 (5.9)

115 (2.9)

30 (0.6)

8 (1.5)

22 (0.5)

29 (0.7)

4 (0.8)

25 (0.6)

Hepatitis C infection

633 (12.3)

106 (19.7)

527 (11.4)

436 (9.8)

90 (18.9)

346 (8.7)

Depression

795 (154)

105 (19.6)

690 (14.9)

955 (21.4)

134 (28.2)

821 (20.6)

Psychotic disorder

329 (6.4)

31 (5.8)

298 (6.5)

297 (6.7)

38 (8.0)

259 (6.5)

Migraine/headache

50 (1.0)

6 (1.1)

44 (1.0)

73 (1.6)

8 (1.7)

65 (1.6)

Any fracture

135 (2.6)

17 (3.2)

118 (2.6)

74 (1.7)

8 (1.7)

66 (1.7)

Surgery history

43 (0.8)

7 (1.3)

36 (0.8)

62 (1.4)

6 (1.3)

56 (1.4)

987 (19.2)

116 (21.6)

871 (18.9)

876 (19.6)

118 (24.8)

758 (19.0)

Alcohol abuse

494 (9.6)

66 (12.3)

428 (9.3)

320 (7.2)

38 (8.10)

282 (7.10)

Drug abuse

937 (18.2)

145 (27.0)

792 (17.2)

913 (20.5)

157 (33.0)

756 (19.0)

Tobacco use disorder

478 (9.3)

61 (11.4)

417 (9.0)

356 (8.0)

48 (10.1)

308 (7.70)

disease

Metastatic solid
tumor
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Opportunistic
infection

Table 4.3. (continued)

Pain-related disorder
Back pain

421 (8.2)

88 (16.4)

333 (7.2)

368 (8.3)

64 (13.5)

304 (7.6)

Neck pain

146 (2.8)

29 (5.4)

117 (2.5)

131 (2.9)

16 (3.4)

115 (2.9)

1,040 (20.2)

164 (30.5)

876 (19.0)

932 (20.9)

144 (30.3)

788 (19.8)

Neuropathy pain

501 (9.7)

96 (17.9)

405 (8.8)

437 (9.8)

67 (14.1)

370 (9.3)

Unclassified pain

122 (2.4)

25 (4.7)

97 (2.1)

291 (6.5)

37 (7.8)

254 (6.4)

None

1,811 (35.1)

148 (27.6)

1,663 (36.0)

1,724 (38.7)

140 (29.4)

1584 (39.8)

1-4

2,773 (53.8)

301 (56.1)

2,472 (53.5)

2,340 (52.5)

262 (55.0)

2,078 (52.2)

5+

570 (11.1)

88 (16.4)

482 (10.4)

396 (8.9)

74 (15.6)

322 (8.1)

Pain medication

1,087 (21.1)

159 (29.6)

928 (20.1)

1,197 (26.8)

177 (37.2)

1,020 (25.6)

Benzodiazepine

530 (10.3)

102 (19.0)

428 (9.3)

409 (9.2)

88 (18.5)

321 (8.1)

Gabapentinoid

330 (6.4)

58 (10.8)

272 (5.9)

246 (5.5)

56 (11.8)

190 (4.8)

Antidepressant

1,249 (24.2)

188 (35.0)

1,061 (23.0)

1,301 (29.2)

215 (45.2)

1,086 (27.3)

Antipsychotics

623 (12.1)

76 (14.2)

547 (11.9)

619 (13.9)

104 (21.9)

515 (12.9)

Any opioid use

1,551 (30.1)

261 (48.6)

1,290 (27.9)

1,498 (33.6)

254 (53.4)

1,244 (31.2)

Arthritis/ joint pain

Number of medications
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All results presented are N (%) unless otherwise noted
*American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian, more than one race

Figure 4.1. Sample selection flowchart
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Note: Generalized estimate equation multivariable logistic regressions, accounting for
clustering at the state level, were used and the reduced model was selected by backward
selection
Figure 4.2. Forest plot presenting the predictors (reduced model) of long-term opioid use
in male (A) and female (B) Medicaid beneficiaries with patients with HIV
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CHAPTER 5. THE EFFECT OF LONG-TERM OPIOID USE ON HEALTHCARE
UTILIZATION IN MEDICAID BENEFICIARIES WITH HIV WHO INITIATED
ANTIRETROVIRAL THERAPY
Abstract
Background: Chronic pain is common among patients diagnosed with HIV, with about half
receiving opioid prescriptions. The potential effect of opioids on immune function,
combined with their misuse potential, calls for a thorough investigation of benefits and
risks opioid prescribing, especially long-term use in vulnerable populations.
Objectives: To examine the healthcare utilization associated with long-term opioid use in
patients with HIV, compared to a group of patients with HIV with no long-term opioid use.
Methods: Using Medicaid data (2002-2009) from four US states [Kentucky, Maryland,
North Carolina, and Washington], we conducted a retrospective cohort study to examine
the impact on healthcare utilization of long-term opioid use in patients with HIV initiating
combined antiretroviral therapy (cART). Long-term opioid use was defined as 90 days of
continuous use over a six-month period, accepting  32 days gap (index date). We had two
different approaches for the outcomes of interest: (1) emergency department (ED)
admissions and HIV-related hospitalizations; and (2) discontinuation of and switching
ART. For the first outcomes of interest, ED admissions and HIV-related hospitalizations,
the unexposed group was selected using incidence density sampling (1:5 ratio and matched
on year of starting cART) among HIV diagnosed beneficiaries. Zero-inflated negative
binomial and Cox proportional hazard regressions were used. For the second outcomes of
interest, discontinuation of and switching ART, beneficiaries with HIV who had standard
ART prescription at the index date were included as an exposure group. The unexposed
group of no long-term opioid users was selected using incidence density sampling (1:4
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ratio), who had standard ART at the matched index date. Cox proportional hazard
regressions were used. Confounders (demographics, comorbidities, other medications)
were selected using causal diagrams and were measured six-months prior to the start date
of long-term opioid use. We estimated adjusted rate ratios (aRR) and hazard ratios (aHR)
with 95% confidence intervals (CI).
Results: Among 9,615 eligible Medicaid enrollees, 1,011 were identified as long-term
opioid users [mean (SD) age: 43.5 (7.6) years; 53% male], and 5,055 were selected for the
unexposed group [mean (SD) age: 41.1 (9.9) years; 53.2% male]. The median follow-up
time was 673 and 528 days for the exposed and unexposed groups, respectively. Overall
rates of ED visit [6.0 vs. 3.3 per 1,000 person-days] and HIV-related hospitalization [1.7
vs. 0.8 per 1,000 person-days] were higher in the exposed group compared to the
unexposed group. Long-term opioid use in the patients with HIV was associated with
increased risk of ED visits [aRR (95% CI): 1.3 (1.2-1.5); aHR (95% CI): 1.1 (1.0-1.2)] and
HIV-related hospitalizations [aRR (95% CI): 1.3 (1.1-1.6); aHR (95% CI): 1.3 (1.1-1.4)].
For the second outcomes of interest, 655 long-term opioid users [mean (SD) age: 43.6 (7.4)
years; 55.3% male] and 2,620 non-users [mean (SD) age: 41.5 (9.8) years; 53.2% male]
were included. The median follow-up time was 707 days and 636.5 days for exposed and
unexposed groups, respectively. Long-term opioid use was associated with decreased risk
of discontinuation of ART [aHR (95% CI): 0.9 (0.8-1.0)] and not significant decreased risk
of switching ART [aHR (95% CI): 0.8 (0.6-1.0)].
Conclusions: Long-term opioid use was associated with increased risk of ED admissions
and HIV-related hospitalizations and decreased risk of discontinuation of ART in HIV-
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diagnosed Medicaid beneficiaries. Further studies are needed to determine whether this
association is causal.
5.1

Introduction
The prevalence of chronic pain in Human Immunodeficiency Virus (HIV) patients

ranges from 39% to 85% [64, 65], and half of the patients with HIV filled the prescriptions
for opioids [66]. Given the concern about increased adverse effects (e.g., drug addiction,
overdose, and increased mortality related to chronic opioids) [4], opioids should be
prescribed with caution after a full evaluation of benefits and risks. Among patients with
HIV, an increased risk of mortality rate has been reported in long-term opioid users [90]
and in high-dose opioid use [91]. Patients with HIV have a high rate of drug abuse history
[19]. Moreover, several studies have demonstrated that opioids affect immune functions
[20, 21], indicating that prescribing opioids may result in a reduction of CD4-positive cells
level in patients with HIV. Furthermore, since antiretroviral agents (ARVs) have the
potential for drug-drug interactions with opioids [64, 89, 92], these unpredictable
interactions could not only modulate the blood levels of opioids and ARVs but also bring
opioid-related adverse effects and progression of HIV infection.
Although the Centers for Disease Control and Prevention (CDC) reported
guidelines for opioid use for chronic pain [13], no exact guidelines for patients with HIV
have been provided. In 2017, the HIV medicine association of Infectious Diseases Society
of America provided guidelines to manage chronic pain in patients living with HIV. This
guideline suggests opioid therapy should not be used as a first-line agent for patients with
HIV, and clinicians should consider a time-limited trial of opioid therapy when the firstline agent did not work [93]. Nonetheless, a recent study using participants in Veteran
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Aging Cohort Study from 2002 to 2018 have reported that 1 in 15 patients with HIV had
escalating opioid use overtime with a potential risk of misuse [94], and several studies have
reported that guideline-concordant of opioid therapy is rare in patients with HIV [95, 96].
Therefore, the purpose of this study was to examine the association between longterm opioid use and healthcare utilizations, such as hospitalization, emergency department
(ED) admission, and switch from/discontinuing ART, in patients with HIV. This study can
have a direct impact on guiding and treating patients with HIV with chronic pain.
5.2

Methods
Data source and study population
We used Medicaid administrative data (2002-2009) obtained from the Centers for

Medicaid and Medicare Services. Medicaid covers the most vulnerable population in the
US, including people with low income, pregnant women, and people with disabilities [97].
This study used the Medicaid Analytic eXtract (MAX) claims files, including personal
summary file (PS), inpatient (IP), prescription (RX), and other services (OT) from four
states (Kentucky (KY), Maryland (MD), North Carolina (NC), and Washington (WA)).
Beneficiaries with HIV were identified based on prescription claims of standard
combination antiretroviral therapy (cART) with the same dispensing date (i.e., cohort entry
date) for at least seven days’ supply from RX file. Standard cART regimens included two
nucleoside reverse transcriptase inhibitors (NRTIs) with one of non-nucleoside reverse
transcriptase inhibitor (NNRTI), integrase strand transfer inhibitor (INSTI), or protease
inhibitor (PI). The drug name and class of ART were identified from the Medicaid data
using national drug codes (NDC) linked with Medispan Generic Product Identifiers (GPI),
starting with ‘121’. Inclusion criteria were: (1) Medicaid eligible beneficiaries between
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2002 and 2009; (2) 18 and older or less than 65 years of age at the cohort entry date; and
(3) continuous eligibility for at least six months prior to the cohort entry date allowing less
than 32 days gap (i.e., washout period). We excluded the beneficiaries if (1) they filled
prescriptions of standard cART medications and long-term opioids during washout period;
(2) had no medical or prescription claims during the washout period; or (3) no available
follow-up after meeting the long-term opioid use definition. The beneficiaries were
censored at the earliest of: (1) a gap in enrollment, allowing less than 32 days gap; and (2)
the end of the study period (December 31, 2009).
Emergency department admissions and HIV-related hospitalizations
5.2.2.1 Exposure
Opioid drugs were identified using NDC linked with Medispan GPI (starting with
‘65’). There is no gold standard definition for long-term opioid use; thus, we followed the
definition, at least 90 days of continuous use of opioids (accepting less than or equal to 32
days of the prescription gap) with multiple opioid prescription claims in a six months
period, which was used in several previous studies [74-76]. The index date for the exposure
group was defined as the date the long-term opioid use criteria were met. The comparison
group, patients with HIV with no long-term opioid use (defined as non-users), was selected
using incidence density sampling method [98], after stratifying the sample by the year of
cohort entry to adjust for the wide time range (2002-2009) of this study. Incidence density
sampling allowed for this study to adjust for the time to exposure. For each long-term
opioid user, time to the long-term opioid start date (Day X) and index date (Day A) was
calculated from the cohort entry date (Day 0). Five non-users were selected from all
persons at risk (i.e., risk set) at the time of exposure (Day A) without replacement,
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excluding the index long-term opioid use itself. The non-user was allowed to be a longterm opioid user later in the follow-up, and this person was censored when they met the
long-term opioid use criteria (Figure 5.1A). The index date and long-term opioid start date
of non-user were calculated based on the matched long-term opioid user’s Day A and Day
X, respectively (Figure 5.1B).
5.2.2.2 Outcomes
The outcomes of interest included ED admissions and HIV-related hospitalizations.
We used IP files with revenue code of “45X” or “981” and OP files with revenue code of
“45X” or “981” or procedure code “99281” through “99285” to identify any ED admissions
[99, 100]. Also, HIV-related hospitalizations were defined as having International
Classification of Disease, ninth edition (ICD-9) diagnosis code including “042” through
“044.9” in the primary and secondary diagnoses from the IP files [77].
Discontinuation of and switching ART
5.2.3.1 Exposure
For this aim, only long-term opioid users taking standard ART regimen at the index
date were included (long-term opioid users). Since there is a possibility of beneficiaries fill
the prescription of each ARV on a different date, we extended seven days of days of supply
for each prescription (e.g., expected end date of prescription=prescription filled date + days
of supply + 6). The comparison group (non-users) was selected using the incidence density
sampling method, adjusting for the time to exposure of the long-term opioid users. We
excluded the beneficiaries not taking standard ART regimen at the assigned index date
from each risk set. Subsequently, four non-users per long-term opioid user were randomly
selected without replacement.
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5.2.3.2 Outcomes
Beneficiaries with discontinuation of ART was defined as who did not start any
drugs in the regimen within 45 days after the index date (Figure 5.2A) or if they started
any drugs in the regimen within 45 days, we allowed additional 15 days to fill all the drugs
in the regimen (Figure 5.2B). We censored the beneficiaries with less than 60 days of
follow-up after the expected end date of prescription (Figure 5.2C). Beneficiaries with
switching cART were defined as those who changed and reduced any classes and added a
new class to the standard ART that was used at the index date within 60 days after the
expected end of the prescription (Figure 5.2D). Adding or changing within the same class
in the regimen was not considered as switching ART. The classes of ARV included NRTI,
NNRTI, INSITI, and PI. For the multi-combination drugs with several classes of drugs in
a single pill, the classes of the regimen were identified as each class of drugs in a single
pill. The beneficiaries who discontinued for 60 days after the expected end date of
prescription (Figure 5.2E) or had less than 60 days of follow-up after the expected end date
of prescription (Figure 5.2F) were censored at the 60 days after the expected end date of
prescription or end of the study period, respectively. The follow-up time of measuring
discontinuation (45 days) and switching cART (60 days) were determined based on a study
conducted by Korsnes et al [101].
Adherence to standard ART
We calculated the proportion of days covered (PDC) from the cohort entry date to
start-date of long-term opioid (PDC-start), from the long-term opioid start-date to index
date (PDC-mid), and from index date to the earliest of (1) censored; (2) end of the study
period (PDC-follow-up) to measure the adherence to a standard cART regimen (Figure
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5.3). Among the sample (long-term opioid users and non-users) that we used for examining
ED admissions and hospitalizations, we included the beneficiaries who had standard cART
at the cohort entry date, at the start date of long-term opioid, and at the index date for
calculating PDC during PDC-start, PDC-mid, and PDC-follow-up, respectively. For the
comparison group, the assigned long-term opioid start date and index date were used to
calculate PDC during three-time frames.
Covariates
We used causal diagram [102, 103] to select confounders. The directed acyclic
graphs (DAG) [56] and the results from DAG are presented in the supplementary (Figure
5.1s & Table 5.1s). We selected the minimal set of measurable confounders (model one
was selected) in our data set (Table 5.1s). The demographic information, such as age, sex,
state, and race, was measured at the cohort entry, and the medical history, such as Charlson
Comorbidity Index (CCI), abuse disorder, tobacco disorder, hepatitis C infection, diabetes,
depression, psychotic disease, fractures, hypertension, opportunistic infection, any caner,
pain-related disease, neuropathy pain, and surgery history, were measured six-month prior
to the start date of long-term opioid use using ICD-9 codes from IP and OT files.
Medication information, such as benzodiazepine, gabapentinoid, pain medication,
antidepressant, antipsychotic, and any opioid, was assessed six-months prior to the start
date of long-term opioid use (i.e., pre-opioid washout period) from the RX file.
Polypharmacy was defined as the number of unique medications, excluding any ARVs and
opioids, three-months prior to the start date of long-term opioid use. For examining the
effect of long-term opioid use on discontinuation of and switching ART, the previous
history of discontinuation of or switching ART was assessed from index date to the six-
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months prior to the index date. The detailed information with the ICD-9 codes and GPI that
we used to identify the covariates in the dataset is presented in Table 5.2s.
Statistical Analysis
The characteristics of beneficiaries between long-term opioid users and non-users
were compared using the Pearson-Chi-Square test, t-test, and Mann-Whitney test for
categorical variables, continuous variables, and continuous variables when the distribution
was not normal, respectively.
To measure the rate of ED visits and HIV-related hospitalizations, the number of
each outcome was calculated, and the person-time was calculated as the time from the
index date to the earliest of (1) outcome occurrence; (2) a gap in enrollment (allowing less
than 32 days gap); and (3) the end of the study period. The offset was the natural log of the
person-time. Considering the possibility of overdispersion and excess zero distribution of
ED visit and hospitalization outcomes, Poisson model, zero-inflated Poisson model,
negative binomial model, and zero-inflated negative binomial model were tested. The
optimal model was determined by checking the overdispersion, the Voung test, and the
Akaike information criterion (AIC) with the smallest value. The unadjusted rate ratio (RR)
and the adjusted rate ratio(aRR) with 95% confidence intervals (CI) were obtained from
the final optimal model.
Cox proportional hazard regressions were performed to examine the risk of ED
admissions, HIV-related hospitalizations, discontinuation of ART, and switching ART in
long-term opioid users. The time was measured from the index date to the earliest of (1)
outcome occurrence; (2) a gap in enrollment; (3) the end of study period; and (4) in case
of switching ART, discontinuation of ART for more than 60 days. For the comparison
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group, the time was measured from the index date to the earliest of (1) outcome occurrence;
(2) a gap in enrollment; (3) the end of study period; (4) transfer to exposure group; and (5)
in case of switching ART, not filling prescription of standard ART for more than 60 days.
Unadjusted hazard ratios (HR) and adjusted hazard ratios (aHR) with 95% CI were
obtained from the multivariable models.
To measure the adherence to a standard ART, the total days of covered with the
standard cART regimen was divided by the total number of days for three different periods,
cohort entry date to long-term opioid start date (PDC-start), long-term opioid start date to
index date (PDC-mid), and index date to the earliest of (1) censored; and (2) end of the
study period (PDC-follow-up) for each beneficiary. The mean (SD) was compared using ttest between long-term opioid users and non-users for each time frame. Additionally, the
mean difference for each time frame was compared between long-term opioid users and
non-users. As a sensitivity analysis, we observed the follow-up time for a maximum of six
months for each period. In other words, the days covered by standard ART and a total
number of days were measured from cohort entry date to the earliest of (1) start date of
long-term opioid use; and (2) 183 days after the cohort entry date, from the long-term
opioid start date to the earliest of (1) index date; and (2) 183 days after long-term opioid
start date, and from index date to the earliest of (1) end of the study period; and (2) 183
days after index date for PDC-start, PDC-mid, and PDC-follow-up, respectively (Figure
5.3). All data analyses were conducted using SAS 9.4®, and 0.05 was set as the
significance level.
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5.3

Results
Emergency department admissions and HIV-related hospitalizations
Among 9,615 Medicaid beneficiaries with HIV, 1,011 long-term opioid users were

identified, and 5,055 non-users were randomly selected and matched on the exposure time
using incidence density sampling (Figure 5.4). The median (IQR) follow-up day was 528
(201-1,041) and 673 (292-1,302) days for non-users and long-term opioid users,
respectively. The mean (SD) age was significantly older in long-term opioid users (43.5
(7.6) years) than in non-users (41.1 (9.9) years). The majority sex and race were male (longterm opioid users: 53%; non-users:53.2%) and black (long-term opioid users: 67.8%; nonusers:72.6%) in both groups. Half of the long-term opioid users (50.1%) were from MD,
and approximately half of the non-users (45.9%) were from MD. Most of the comorbidities
and medications showed significantly higher prevalence in long-term opioid users than in
non-users, except for psychotic disease (long-term opioid users: 7.9% vs. non-users: 6.4%,
p-value: 0.08) and surgery history (long-term opioid users: 0.9% vs. non-users: 1.2%, pvalue: 0.48). More than half of the long-term opioid users (65.4%) reported taking five or
more medications; whereas, 39.3% of non-users reported taking five or more medications
(Table 5.1).
Since overdispersion occurred using the Poisson model and exceeding zero counts
was observed for the ED visits (49.7%) and HIV-related hospitalizations (76.3%), zeroinflated negative binomial was selected as the optimal model for this current study. During
the follow-up, 63.2% and 47.8% of long-term users and non-users, respectively, had ED
admissions at least once. The overall rates of ED admissions were higher in the long-term
opioid users (6.02 per 1,000 person-days) than in the non-users (3.27 per 1,000 person-
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days). After adjusting for confounders, the rate ratio showed that beneficiaries with longterm opioid use had an increased rate of ED visit after index date than in non-users (aRR:
1.34; 95% CI: 1.20, 1.50) (Table 5.2). The overall prevalence of having at least one HIVrelated hospitalization was higher in long-term opioid users (38.0%) than in non-users
(20.8%) during the follow-up. The overall rates of hospitalization were 1.68 per 1,000
person-days and 0.77 per 1,000 person-days for long-term opioid users and non-users,
respectively. The unadjusted (RR: 1.69; 95% CI: 1.43, 1.99) and the adjusted (aRR: 1.34;
95% CI: 1.12, 1.62) rate ratios showed that beneficiaries with long-term opioid use had
increased rate of hospitalization compared to the beneficiaries with non-use. After
adjusting for confounders, the risks of ED visit and hospitalization were 11% and 27%,
respectively, higher in long-term opioid users compared to non-users (aHR: 1.11; 95% CI:
1.01, 1.22; aHR: 1.27; 95% CI: 1.11, 1.44, respectively) (Table 5.2).
Discontinuation of and switching ART
Among 1,011 long-term opioid users, 655 beneficiaries filled the standard ART regimen
at the index date. Non-users (N=2,620) were randomly selected from the study sample
matched on the exposure time of long-term opioid users. The median (IQR) follow-up day
was 636.5 (263.5-1,232.5) days for non-users and 707 (312-1,342) days for long-term
opioid users. The patterns of demographic information, comorbidities, and use of
medications were similar to the study sample that was used for examining ED admissions
and HIV-related hospitalizations (Table 5.3).
Overall, the prevalence of discontinuation of ART was 59.7% (long-term opioid
users) and 59.2% (non-users) and switching ART was 8.6% (long-term opioid users) and
10% (non-users). After adjusting for the confounders, long-term opioid use was associated
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with a significant decrease in the risk of discontinuation of ART (aHR: 0.85; 95% CI: 0.75,
0.96), whereas no significant difference was observed in the risk of switching ART
associated with long-term opioid use (aHR:0.77; 95% CI: 0.56, 1.04) (Table 5.4).
Proportion of days covered
Totals of 4,825 non-user beneficiaries and 965 long-term opioid user beneficiaries
were included to measure PDC-start. The number of beneficiaries included in PDC-start
was less than the total sample size (6,066) because the beneficiaries who entered the cohort
and started long-term opioid at the same date were excluded. The mean (SD) follow-up
was 562.4 (525.0) days and 562.4 (525.2) days for non-users and long-term opioid users,
respectively. For PDC-mid, 2,613 non-users and 637 long-term opioid users were included.
The mean (SD) follow-up was 118.7 (26.1) days and 119.1 (26.8) days for non-users and
long-term users, respectively. There were 2,172 non-users (mean (SD) follow-up: 767.1
(641.6)) and 655 long-term opioid users (857.5 (656.6)) included to examine PDC-followup. The PDCs during PDC-mid were significantly different between non-users and longterm opioid users (p-value: < 0.0001); whereas, no significant differences were observed
for comparing non-users to long-term users during PDC-start and PDC-follow-up.
However, the changes of PDC from PDC-start to PDC mid were +11.5 and +21.2 for nonusers and long-term opioid users, respectively, and the changes of PDC from PDC-mid to
PDC-follow-up were -11.8 and -21.5 for non-users and long-term opioid users, respectively
(Figure 5.3A). The same patterns were observed in the sensitivity analysis (Figure 5.3B),
which we restricted the follow-up time up to six months. The PDC changes from PDC-mid
to PDC-follow-up were +0.9 and -8.1 for non-users and long-term opioid users,
respectively.
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5.4

Discussion
This study examined the effect of long-term opioid use on healthcare utilization in

Medicaid beneficiaries with HIV who initiated standard cART. We found that long-term
opioid use in Medicaid beneficiaries with HIV was significantly associated with increased
risk of ED admissions and HIV-related hospitalizations and decreased risk of
discontinuation of ART. However, no significant effect of long-term opioid use was
observed on switching ART.
The increased risk of ED admissions and HIV-related hospitalizations in our study
were consistent with other studies measuring adverse outcomes. A retrospective study
using data from the Seek and Treat for Optimal Prevention of HIV/AIDS in British
Columbia, Canada, found that mortality rates were significantly higher in patients with
HIV with high-dose opioid use compared to those with lower dose opioid use [91]. Another
study conducted by Weisberg et al. examined that long-term opioid use in patients with
HIV was associated with an increased risk of mortality using data from Veterans Aging
Cohort Study-Virtual Cohort [90]. A study including patients with HIV in a medical center
found that long-term opioid use was associated with increased healthcare utilization,
including ED visits and hospitalizations, but the result was not significant due to the small
sample size (117 long-term opioid-users and 209 non-users) [104]. Further studies are
needed to investigate whether this association is causal.
We hypothesized that the risk of discontinuation and switching ART would
increase in long-term opioid users compared to non-users due to the drug-drug interaction
between ARVs and opioid and CD4 cell change by using opioids. However, the risk of
discontinuation of ART was decreased in the long-term opioid users than in non-users. A
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study conducted by Crawford et al. found that patients with HIV with non-HIV related
comorbidities (renal disease, cancer, cardiovascular, cerebrovascular, respiratory, diabetes,
and depression) had better retention in care compared to those patients with HIV with no
comorbidities [105]. In our study, the characteristics of long-term opioid users and nonusers showed that long-term opioid users are sicker with more comorbidities and
medications (Table 5.3). Thus, there is a possibility that long-term opioid users seek
medical care more often than non-users, leading them to continue their standard ART
regimen without discontinuing.
Since not all of the drugs in ARVs are done for pharmacokinetic studies to examine
ARV-opioid interactions [64, 92] and opioids are also known to affect the number of CD4
cell [20, 21], we addressed switching ART across the classes in this study to examine the
overall effects. However, the effects of drug-drug interaction on ARV is drug-specific, the
known ARVs that its blood levels are affected by opioids, especially methadone or
buprenorphine, include NRTIs (didanosine, zidovudine, and stavudine) and PIs
(Amprenavier, Indinavir, and Nelfinavir) [64, 92]. Therefore, further studies are needed to
address the effect of long-term opioid use on switching ART after subgrouping the ARVs.
We found that there was no significant effect of long-term opioid use on PDC
compared to non-use PDC-follow-up. However, the PDC change from PDC-mid to PDCfollow-up was larger in long-term opioid users than that in non-users. Since long-term
opioid users went to the hospital to fill the prescription of opioids during PDC-mid, there
is a possibility that the adherence to standard ART was high at that time. Further studies
could examine whether other controlled substances (e.g., benzodiazepine) have a similar
pattern of PDC change as standard cART.
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This study has several strengths and limitations. Non-users were selected using
incidence density sampling accounting for the time to exposure to reduce bias. Also, we
used a new-user design with six months washout period to identify long-term opioid users
and beneficiaries with HIV who initiated standard ART. However, we allowed the
beneficiaries to fill any opioids during the washout period instead of identifying opioidnaïve long-term opioid users due to the small sample size. To avoid any bias from the
prevalent any opioid users, we included a previous history of any opioid use as a
confounder. Since claims data are collected in billing purposes, not for research, potential
coding errors and missing data could present. Although claims data have unmeasured
confounders, the causal diagram allowed us to select a minimal set of essential confounders
without including the unmeasured confounders. For example, unmeasurable variables,
patients’ income or lifestyle, were not necessary to be included in the adjusting covariates
based on minimal sufficient sets from the causal diagram. However, we could not adjust
for the severity of the disease because the CD4 cell count data was unavailable. Also, filling
the prescriptions does not mean that the patient actually took the medication. Additionally,
since we selected long-term opioid users with the beneficiaries who filled prescriptions of
standard ART at the index date, there could have potential selection bias in this study.
However, the characteristics of beneficiaries between who filled standard ART at the index
date and who didn’t fill the standard ART showed that the characteristics of the two groups
were similar (Table 5.3s), which means that there is low possibility of having selection
bias.
In conclusion, the present study examined that long-term opioid use was associated
with increased risk of ED visit and HIV-related hospitalization, and decreased risk of
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discontinuing ART. Further studies are required to determine whether this association is
causal, and more investigation is needed to examine the effect of long-term opioid use on
switching ART after refining the definition of switching ART.
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Table 5.1. Characteristics of beneficiaries for measuring ED admissions and HIV-related
hospitalizations
Long-term opioid
Non-users
users
p-value
(N=5,055)
(N=1,011)
Age (mean (SD))

43.5 (7.6)

41.1 (9.9)

<.0001

Female

475 (47.0)

2,367 (46.8)

0.91

Kentucky

40 (4.0)

203 (4.0)

0.02

Maryland

506 (50.1)

2,322 (45.9)

North Carolina

333 (32.9)

1,918 (37.9)

Washington

132 (13.1)

612 (12.1)

White

265 (26.2)

1,024 (20.3)

Black

685 (67.8)

3670 (72.6)

61 (6.0)

361 (7.1)

CCI (mean (SD))

1.37 (1.93)

0.64 (1.24)

<0.0001

Abuse disorder

350 (34.6)

1,066 (21.1)

<0.0001

Tobacco disorder

149 (14.7)

359 (7.1)

<0.0001

Hepatitis C infection

190 (18.8)

515 (10.2)

<0.0001

Diabetes

115 (11.4)

388 (7.7)

<0.0001

Hypertension

292 (28.9)

921 (18.2)

<0.0001

Depression

291 (28.8)

897 (17.7)

<0.0001

80 (7.9)

325 (6.4)

0.08

Pain related disease

533 (52.7)

1,333 (26.4)

<0.0001

Neuropathy pain

224 (22.2)

484 (9.6)

<0.0001

Fractures

47 (4.7)

107 (2.1)

<0.0001

Any Cancer

83 (8.2)

156 (3.1)

<0.0001

Surgery history

9 (0.9)

58 (1.2)

0.48

Opportunistic infection

223 (22.1)

626 (12.4)

<0.0001

Benzodiazepine

234 (23.2)

508 (10.1)

<0.0001

State

Race

Other* or Unknown

Psychotic disease
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0.0001

Table 5.1. (continued)
Gabapentinoid

172 (17.0)

333 (6.6)

<0.0001

Pain medication

430 (42.5)

1275 (25.2)

<0.0001

Antidepressant

470 (46.5)

1,396 (27.6)

<0.0001

Antipsychotic

226 (22.4)

701 (13.9)

<0.0001

Any opioids

564 (55.8)

1,461 (28.9)

<0.0001

83 (8.2)

1,220 (24.1)

<0.0001

1-4

267 (26.4)

1,849 (36.6)

5+

661 (65.4)

1,986 (39.3)

Number of medications
None

(All results presented are N (%) unless otherwise noted)
*American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian,
More than one race
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Table 5.2. Zero-inflated negative binomial and Cox proportional hazard analyses of
emergency department (ED) admissions and HIV-related hospitalizations associated with
long-term opioid use
Incidence Rate Ratio (95% CI)
Hazard Ratio (95% CI)
Unadjusted

Adjusted

Unadjusted

Adjusted

1.83

1.34

1.36

1.11

(1.63, 2.04)

(1.20, 1.50)

(1.25, 1.48)

(1.01, 1.22)

HIV-related

1.69

1.34

1.80

1.27

hospitalizations

(1.43, 1.99)

(1.12, 1.62)

(1.60, 2.02)

(1.11, 1.44)

ED admissions
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Table 5.3. Characteristics of beneficiaries included in the analyses of discontinuing of
and switching ART
Long-term opioid
Non-users
p-value
users (N=655)
(N=2,620)
Age (mean (SD))

43.63 (7.39)

41.54 (9.82)

<.0001

292 (44.7)

1226 (46.8)

0.33

Kentucky

23 (3.5)

88 (3.4)

0.12

Maryland

324 (49.5)

1194 (45.6)

North Carolina

216 (33.0)

997 (38.1)

Washington

92 (14.1)

341 (13.0)

White

185 (28.2)

568 (21.7)

Black

433 (66.1)

1861 (71.0)

37 (5.7)

191 (7.3)

CCI (mean (SD))

1.31 (1.85)

0.64 (1.17)

<0.0001

Abuse disorder

222 (33.9)

517 (19.7)

<0.0001

Tobacco disorder

96 (14.7)

185 (7.1)

<0.0001

Hepatitis C infection

136 (20.8)

310 (11.8)

<0.0001

Diabetes

73 (11.2)

197 (7.5)

0.003

Hypertension

183 (27.9)

515 (19.7)

<0.0001

Depression

192 (29.3)

502 (19.2)

<0.0001

45 (6.9)

175 (6.7)

0.86

Pain related disease

337 (51.5)

710 (27.1)

<0.0001

Neuropathy pain

150 (22.9)

254 (9.7)

<0.0001

Fractures

30 (4.6)

54 (2.1)

<0.0003

Any Cancer

50 (7.6)

81 (3.1)

<0.0001

Surgery history

5 (0.8)

34 (1.3)

0.26

Opportunistic infection

138 (21.1)

293 (11.2)

<0.0001

Benzodiazepine

148 (22.6)

246 (9.4)

<0.0001

Gabapentinoid

120 (18.3)

196 (7.5)

<0.0001

Female (missing=2)
State

Race

Other* or Unknown

Psychotic disease
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0.001

Table 5.3. (continued)
Pain medication

285 (43.5)

767 (29.3)

<0.0001

Antidepressant

323 (49.3)

909 (34.7)

<0.0001

Antipsychotic

147 (22.4)

473 (18.1)

0.01

Any opioids

365 (55.7)

799 (30.5)

<0.0001

42 (6.4)

270 (10.3)

<0.0001

1-4

169 (25.8)

1087 (41.5)

5+

444 (67.8)

1263 (48.2)

Number of medications
None

(All results presented are N (%) unless otherwise noted)
*American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian,
More than one race
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Table 5.4. Cox proportional hazard analyses of discontinuing and switching ART
associated with long-term opioid use
Unadjusted HR (95% CI)
Adjusted HR (95% CI)
Discontinuing of ART

0.89 (0.80, 0.99)

0.85 (0.75, 0.96)

Switching ART

0.82 (0.62, 1.10)

0.77 (0.56, 1.04)

HR: Hazard Ratio; CI: Confidence interval
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Note: Day 0=cohort entry date; Day X=long-term opioid start date; Day A and Day A’=
index date (when they meet the criteria of long-term opioid use)
(A) For each long-term opioid user (exposure), risk set was identified from all persons at
risk at the time of exposure (Day A), and five non-users were selected from the risk set.
(B) The index date and long-term opioid start date were assigned to the non-users based on
the matched long-term opioid user’s Day A and Day X
Figure 5.1. Selecting comparison group using incidence density sampling (A) and
calculating matched index date and long-term opioid start date in non-users (B)
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Note: Dayexp=expected end date of prescription
Figure 5.2. Possible scenarios for discontinuation of and switching ART
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Figure 5.3. Change of Proportion of drug covered (PDC) in different time frame (A);
Change of PDC in different time frame following up to 6 months (B)
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Figure 5.4. Sample selection flowchart
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CHAPTER 6. CONCLUSION
The effectiveness of long-term opioid use is still questionable; however, there is
growing evidence for the adverse outcomes associated with long-term opioid use. The CDC
issued guidelines for prescribing opioids for patients with chronic pain [13]. However,
detailed guidelines on prescribing opioids in vulnerable populations are missing due to the
lack of evidence coming from well-conducted valid studies. Therefore, the purpose of this
dissertation research was to build additional evidence by describing patterns and predictors
of long-term opioid use and assessing outcomes related to prescribing opioids chronically
in vulnerable populations. Existing data from National Alzheimer’s Coordinating Center
(NACC) (2005-2017) were used for two research projects: (1) “Patterns and predictors of
chronic opioid use in older adults: a retrospective cohort study,” and (2) “Comparing the
patterns and predictors of opioid use in older adults with different cognitive status,” and
Medicaid claims data from Centers for Medicaid and Medicare Services were used for two
research projects: (3) “An investigation of predictors of long-term opioid use in Medicaid
beneficiaries with HIV who initiated antiretroviral therapy” and (4) “The effect of longterm opioid use on healthcare utilization in Medicaid beneficiaries with HIV who initiated
antiretroviral therapy.”
Chapters two and three described patterns of long-term opioid use in older adults
and older adults with different cognitive status. Older adults and older adults with normal
cognition had four distinct trajectories––minimal-users, incident chronic-users,
discontinuing-users, and prevalent chronic-users. For participants with mildly impaired
cognition and dementia, three distinct trajectories were identified–– minimal-users,
incident chronic-users, and prevalent chronic-users. Further studies are needed to examine
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whether having different patterns of opioid use in participants with mildly impaired
cognition and dementia compared to normal cognition is associated with inappropriate use
of opioids.
Chapters two, three, and four identified predictors of long-term opioid use in
vulnerable populations, including older adults, older adults with dementia, and patients
with HIV. These three research projects showed that the more vulnerable (older age, with
multiple comorbidities, taking medications, and polypharmacy) were more likely to be
become long-term opioid users. While many predictors were shared across different
populations, some of the predictors were population-specific. For example, psychotic
disorder was positively associated with long-term opioid use in older adults, but it was
negatively associated with long-term opioid use in patients with HIV. Having diabetes and
neuropathic pain was associated with long-term opioid use in male beneficiaries with HIV,
but not in the female. Since this study used two different data sources, NACC uniform data
set (UDS) and Medicaid claims data, careful interpretation is needed to compare the
predictors across populations. Further studies are required to further examine the risk of
long-term opioid use in other vulnerable populations.
Chapter five examined the effect of long-term opioid use on healthcare utilization
in Medicaid beneficiaries with HIV. This research project found that long-term opioid use
was associated with an increased risk of healthcare utilization (emergency department
admissions and HIV-related hospitalizations). With respect to discontinuation of and
switching ART, the long-term opioid use was associated with decreased risk of
discontinuation of ART, but was not significantly associated with switching ART. The
decreased risk of discontinuation of ART could be due to a possibility that long-term opioid
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users seek medical care more other than non-users because they are sicker with more
comorbidities and medications. Further studies are needed to examine whether the
increased risk of healthcare utilization associated with long-term opioid use is causal and
to investigate the risk of switching ART after refining the definition of outcomes.
There are several limitations in this dissertation research projects. First,
misclassification bias could exist in both data. Since the medication information from
NACC data is collected within two weeks of the UDS visit, participants could be
misclassified if they used opioids only between visits. Also, beneficiaries who filled the
prescription in Medicaid claims data does not mean that they actually took the medications.
Second, the research projects could have potential selection bias by excluding the
participants with fewer than three visits in NACC data and the beneficiaries who did not
filled prescriptions of standard ART in Medicaid claims data. However, in each chapter,
we conducted sensitivity analyses and investigated that there was little impact on our
findings. In addition, there is a possibility of having unmeasured confounders in NACC
data and Medicaid claims data. We could not assess confounders, such as clinician
characteristics, patients’ lifestyle, and family history of opioid use, from both data, and the
severity of HIV disease (CD4 cell count) and use of over the counter drugs could not be
assessed using Medicaid claims data, Also, since we measured all of the covariates at the
first visit (NACC) or six-months prior to the start date of opioid use (Medicaid), including
time-varying covariates may have resulted in different association. The participants in the
NACC data tend to be highly educated, and the beneficiaries in the Medicaid data are
pregnant women, have low income, or disabilities, which may limit generalizability.
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Finally, the research projects in this dissertation provide a better understanding in
patterns and predictors of long-term opioid use and the outcomes associated with long-term
opioid use in vulnerable populations. Further studies are required to thoroughly address the
risk and benefit of using long-term opioids in vulnerable populations, and it is essential to
provide different guidance on prescribing long-term opioids in different populations to
mitigate adverse outcomes.
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Table 2.1s. List of drugs included in “any opioids” and “strong opioids”
Any opioids: included any opioid analgesic medications
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Acetaminophen-codeine

Acetaminophen-hydrocodone'

Acetaminophen-oxycodone

Acetaminophen-tramadol'

Acetaminophen/butalbital/caffeine/ codeine

Acetaminophen/caffeine/dihydrocodeine

Asa/caffeine/propoxyphene

Aspirin/butalbital/caffeine/codeine

Aspirin/caffeine/dihydrocodeine

Aspirin/carisoprodol/codeine'

Aspirin-hydrocodone

Aspirin-oxycodone

Bupivacaine-fentanyl

Bupivacaine-hydromorphone

Buprenorphine

Codeine

Dihydrocodeine

Droperidol-fentanyl

Fentanyl

Fentanyl topical

Fentanyl-ropivacaine

Hydrocodone

Hydrocodone-ibuprofen

Hydromorphone

Meperidine

Methadone

Morphine

Opium

Oxycodone

Oxymorphone

Propoxyphene

Tramadol

Table 2.1s. (continued)
Strong opioids: included opioids stronger than or equal to morphine’s potency*
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Acetaminophen-hydrocodone

Acetaminophen-oxycodone

Aspirin-hydrocodone

Aspirin-oxycodone

Bupivacaine-fentanyl

Bupivacaine-hydromorphone

Buprenorphine

Droperidol-fentanyl

Fentanyl

Fentanyl topical

Fentanyl-ropivacaine

Hydrocodone

Hydrocodone-ibuprofen

Hydromorphone

Methadone

Morphine

Opium

Oxycodone

Oxymorphone
* Pasero C, McCaffery M. Pain assessment and pharmacologic management. St. Louis, MO: Mosby; 2010.
Horgas AL, Snigurska U, Farland MZ, Marsiske M. Analyzing Analgesic Medications in Community-Dwelling Older
Adults. Pain Med. 2018

Table 2.2s. Description of variables used in the study
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Variables
Baseline age
Female
Race

Form
A1 subject demographics
A1 subject demographics
A1 subject demographics

Education
Type of Residence

A1 subject demographics
A1 subject demographics

Smoking cigarettes
Alcohol abuse

A5 subject health history
A5 subject health history

Other abused
substances

A5 subject health history

Agitation

B9 Clinician Judgement
of Symptoms
A5 subject health history
A5 subject health history
A5 subject health history

Hypertension
Diabetes
Any cardiovascular
disease

Description
Subject’s age at visit
Subject’s sex
White
Black or African American
Others (American Indian, Alaska Native, Native Hawaiian, Pacific
Islander, Asian, or Other)
(Missing=24)
Years of education (0-36) (Missing=40)
Single- or multi- family private residence
Retirement community or independent group living
Assisted living, adult family home, boarding home, skilled nursing
facility, nursing home, hospital, or hospice
Unknown
Smoked cigarettes in last 30 days (yes vs. no) (Missing=51)
Alcohol abuse-clinically significant impairment occurring over a 12month period manifested in one of the following area: work, driving,
legal, or social (ever vs. never) (Missing=28)
Other abused substances - clinically significant impairment occurring over
a 12-month period manifested in one of the following area: work, driving,
legal, or social (ever vs. never) (Missing=34)
Subject currently manifests meaningful change in behavior – agitation
(yes vs. no) (Missing=36)
Hypertension (ever vs. never) (Missing=35)
Diabetes (ever vs. never) (Missing=50)
Any history of Heart attack/cardiac arrest, Atrial fibrillation, Congestive
heart failure, Stroke, or Other cardiovascular disease (ever vs. never)
(Missing=119)

Table 2.2s. (continued)
Urinary
incontinence
Cancer
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Number of
Medications
Antidepressant agent
Antipsychotic agent
Anxiolytic, sedative,
or hypnotic agent
Nonsteroidal antiinflammatory
medication
Dementia

A5 subject health history

Incontinence – urinary (ever vs. never) (Missing=31)

D1 clinician diagnosis
D2 clinician-assessed
medical conditions
A4 subject medications

Presence of cancer (yes vs. no)

A4 subject medications
A4 subject medications
A4 subject medications

Total number of medications reported at the participant’s initial UDS visit
(excluded the number of opioids use at the participant’s initial visit)
Report current use of antidepressant
Report current use of antipsychotic agent
Report current use of anxiolytic, sedative, or hypnotic agent

A4 subject medications

Report current use of nonsteroidal anti-inflammatory medication

B4 global staging
D1 clinician diagnosis
A4 subject medications

Clinician diagnosis (NACCUDSD) of dementia plus Clinician Dementia
Rating (CDR)† score ≥ 1
Medication used within two weeks of UDS visit

Use of opioids
(any and strong)
†CDR score 0: no impairment; 0.5: questionable impairment; 1: mild impairment; 2: moderate impairment; 3: severe
impairment
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.

Table 2.3s. Description of estimated trajectories and number of participants in each
trajectory
Trajectory

N

Polynomiala

Group

Estimates p(SE)b
valuec

Average posterior
probabilityd

Any opioid
Minimal-use

11,806

Cubic

-0.0112
(0.004)

0.003

0.96

Discontinuing use

287

Cubic

0.0305
(0.006)

<0.001

0.72

Incident chronic use

657

Quadratic

-0.0847
(0.011)

<0.001

0.73

Prevalent chronic-use

309

Quadratic

-0.0807
(0.014)

<0.001

0.77

Minimal-use

12,317

Quadratic

0.0094
(0.015)

0.52

0.97

Discontinuing use

116

Quadratic

-0.1867
(0.074)

0.011

0.78

Incident chronic use

444

Quadratic

-0.0803
(0.012)

<0.001

0.71

Prevalent chronic-use

182

Quadratic

-0.0641

<0.001

0.81

Strong opioids

(0.017)
Note: a=highest order of the trajectory group; b=parameter estimates of the highest order
and standard error (SE); c=p-value for the highest order of the trajectory group;
d=average posterior probability for the participants assigned to the trajectory group
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Table 2.4s. Factors associated with chronic-use (prevalent or incident) vs. discontinuing-use and chronic-use (prevalent or
incident) vs. non-use of any opioids in multivariable logistic regression model (full model)
Prevalent chronic-use

Incident chronic-use

vs. discontinuing-use

vs. minimal-use

vs. discontinuing-use

vs. minimal-use

65-74

Ref.

Ref.

Ref.

Ref.

75-84

1.17 (0.80, 1.72)

1.10 (0.84, 1.43)

1.07 (0.76, 1,50)

1.11 (0.92, 1.33)

85+

1.16 (0.69, 1.96)

1.81 (1.26, 2.61)

0.67 (0.41, 1.08)

1.17 (0.89, 1.52)

Female

1.07 (0.72, 1.59)

1.85 (1.40, 2.43)

0.70 (0.51, 0.98)

1.23 (1.03, 1.46)

White

Ref.

Ref.

Ref.

Ref.

Black

1.23 (0.78, 1.93)

1.80 (1.31, 2.46)

0.82 (0.54, 1.25)

1.47 (1.17, 1.84)

Other

0.50 (0.17, 1.52)

0.42 (0.17, 1.05)

0.66 (0.28, 1.52)

0.61 (0.37, 1.03)

1.00 (0.95, 1.05)

0.95 (0.92, 0.99)

1.02 (0.97, 1.06)

0.96 (0.94, 0.99)

Ref.

Ref.

Ref.

Ref.

Independent groupb

1.73 (0.98, 3.04)

1.69 (1.17, 2.43)

2.00 (1.19, 3.35)

1.69 (1.31, 2.18)

Care facilityc

2.70 (0.87, 8.33)

1.90 (1.00, 3.64)

2.21 (0.76, 6.42)

1.78 (1.12, 2.84)

Unknown

1.14 (0.39, 3.34)

0.86 (0.42, 1.78)

0.93 (0.35, 2.47)

0.66 (0.37, 1.18)

0.82 (0.39, 1.72)

1.52 (0.90, 2.56)

0.59 (0.29, 1.19)

1.15 (0.76, 1.75)

Baseline age

Race
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Education (1-year difference)
Type of Residence
Privatea

Current smoking

Table 2.4s. (continued)
Ever alcohol abuse

0.99 (0.45, 2.17)

1.24 (0.72, 2.12)

0.74 (0.37, 1.46)

1.06 (0.72, 1.58)

Ever other abused substances

1.19 (0.27, 5.30)

2.25 (0.84, 6.00)

0.60 (0.12, 3.06)

0.98 (0.34, 2.81)

Agitation

1.59 (0.64, 3.98)

1.04 (0.59, 1.83)

1.08 (0.47, 2.49)

0.77 (0.51, 1.15)

Ever hypertension

0.83 (0.56, 1.23)

1.22 (0.94, 1.59)

0.95 (0.67, 1.34)

1.42 (1.19, 1.71)

Ever diabetes

1.03 (0.65, 1.65)

1.38 (1.00, 1.89)

0.83 (0.55, 1.26)

1.10 (0.87, 1.39)

Ever cardiovascular disease

1.24 (0.85, 1.80)

1.22 (0.94, 1.58)

1.32 (0.94, 1.84)

1.27 (1.06, 1.52)

Ever urinary incontinence

0.60 (0.40, 0.91)

1.04 (0.77, 1.41)

0.78 (0.55, 1.11)

1.43 (1.17, 1.76)

Dementia diagnosis

0.70 (0.40, 1.24)

0.45 (0.30, 0.68)

1.15 (0.73, 1.83)

0.73 (0.57, 0.94)

Ref.

Ref.

Ref.

Ref.

1 to 4

0.69 (0.22, 2.19)

1.31 (0.64, 2.67)

0.23 (0.09, 0.57)

0.48 (0.36, 0.65)

5 or more

0.60 (0.19, 1.85)

2.30 (1.13, 4.67)

0.15 (0.06, 0.38)

0.67 (0.50, 0.90)

Antidepressant agent

1.16 (0.80, 1.68)

1.82 (1.40, 2.37)

0.77 (0.55, 1.08)

1.36 (1.12, 1.66)

Antipsychotic agent

2.58 (0.73, 9.11)

1.24 (0.62, 2.50)

2.99 (0.95, 9.42)

1.29 (0.79, 2.10)

1.06 (0.70, 1.61)

2.23 (1.67, 2.98)

0.56 (0.38, 0.82)

1.24 (0.97, 1.60)

1.47 (1.03, 2.10)

1.37 (1.07, 1.76)

1.03 (0.75, 1.43)

0.93 (0.78, 1.13)

Number of medications
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0

Anxiolytic, sedative, or hypnotic
agent
NSAID

Abbreviations: NSAID, nonsteroidal anti-inflammatory medication.
a=single-or multiple family private living; b=retirement community, or independent group living; c=assisted living, nursing
home, or hospital

Table 2.5s. Factors associated with chronic-use (prevalent or incident) vs. discontinuing-use and chronic-use (prevalent or
incident) vs. non-use of strong opioids in multivariable logistic regression model (full model)
Prevalent chronic-use vs.

Incident chronic-use vs.

discontinuing-use

minimal-use

discontinuing-use

minimal-use

65-74

Ref.

Ref.

Ref.

Ref.

75-84

1.39 (0.78, 2.51)

1.11 (0.79, 1.57)

1.20 (0.71, 2,01)

1.14 (0.92, 1.42)

85+

1.98 (0.86, 4.56)

2.04 (1.29, 3.23)

0.87 (0.42, 1.81)

1.29 (0.94, 1.77)

Female

1.12 (0.62, 2.02)

1.80 (1.26, 2.57)

0.89 (0.54, 1.47)

1.26 (1.02, 1.56)

White

Ref.

Ref.

Ref.

Ref.

Black

1.80 (0.86, 3.77)

1.73 (1.15, 2.60)

0.83 (0.42, 1.64)

1.06 (0.80, 1.42)

Other

1.18 (0.19, 7.50)

0.48 (0.15, 1.54)

1.32 (0.31, 5.65)

0.63 (0.34, 1.17)

1.02 (0.94, 1.11)

0.97 (0.92, 1.01)

1.05 (0.98, 1.12)

0.99 (0.96, 1.02)

Ref.

Ref.

Ref.

Ref.

Independent groupb

1.88 (0.80, 4.45)

1.70 (1.07, 2.69)

2.12 (0.98, 4.57)

1.73 (1.28, 2.33)

Care facilityc

2.43 (0.56, 10.59)

3.47 (1.71, 7.03)

1.40 (0.36, 5.43)

2.06 (1.23, 3.44)

Unknown

8.19 (0.90, 74.93)

1.32 (0.61, 2.89)

3.54 (0.40, 31.50)

0.66 (0.32, 1.35)

0.80 (0.31, 2.08)

2.20 (1.23, 3.95)

0.67 (0.27, 1.67)

1.67 (1.07, 2.60)

Baseline age

Race
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Education (1-year difference)
Type of Residence
Privatea

Current smoking

Table 2.5s. (continued)
Ever alcohol abuse

0.84 (0.30, 2.40)

1.47 (0.77, 2.81)

0.51 (0.21, 1.24)

0.89 (0.54, 1.46)

Ever other abused substances

1.27 (0.16, 9.75)

1.86 (0.53, 6.57)

1.48 (0.22, 10.09)

2.38 (0.97, 5.84)

Agitation

2.01 (0.44, 9.13)

0.84 (0.37, 1.89)

2.04 (0.51, 8.14)

1.02 (0.65, 1.60)

Ever hypertension

0.62 (0.34, 1.11)

1.20 (0.85, 1.68)

0.85 (0.50, 1.44)

1.43 (1.15, 1.78)

Ever diabetes

0.83 (0.41, 1.70)

1.10 (0.71, 1.70)

0.79 (0.42, 1.48)

1.02 (0.76, 1.36)

Ever cardiovascular disease

0.95 (0.55, 1.65)

1.25 (0.90, 1.73)

1.09 (0.67, 1.78)

1.15 (0.93, 1.43)

Ever urinary incontinence

0.43 (0.23, 0.81)

0.94 (0.63, 1.40)

0.58 (0.35, 0.97)

1.39 (1.09, 1.77)

Dementia diagnosis

0.79 (0.33, 1.90)

0.39 (0.23, 0.68)

1.44 (0.70, 2.93)

0.70 (0.52, 0.95)

Ref.

Ref.

Ref.

Ref.

1 to 4

0.63 (0.05, 7.59)

2.50 (0.76, 8.20)

0.09 (0.01, 0.76)

0.48 (0.34, 0.68)

5 or more

0.54 (0.05, 6.33)

4.00 (1.23, 13.06)

0.06 (0.01, 0.44)

0.63 (0.44, 0.91)

Antidepressant agent

1.08 (0.62, 1.89)

1.88 (1.35, 2.62)

0.76 (0.47, 1.23)

1.53 (1.22, 1.93)

Antipsychotic agent

2.42 (0.36, 16.09)

0.95 (0.36, 2.48)

2.17 (0.43, 11.02)

1.23 (0.69, 2.19)

Anxiolytic, sedative, or hypnotic
agent
NSAID

1.19 (0.65, 2.17)

2.53 (1.77, 3.62)

0.47 (0.27, 0.83)

1.14 (0.84, 1.54)

1.95 (1.13, 3.36)

1.28 (0.93, 1.76)

1.21(0.74, 2.00)

0.86 (0.69, 1.08)

Number of medications

113

0

Abbreviations: NSAID, nonsteroidal anti-inflammatory medication.
a=single-or multiple family private living; b=retirement community, or independent group living; c=assisted living, nursing
home, or hospital

Table 2.6s. The frequency distribution across trajectory groups of any opioid use among
Alzheimer’s Disease Centers (ADC)
ADC

Minimal

Discontinuing

N (%)

(N=11,806)

(N=287)

289

359 (94.2)

6 (1.6)

9 (2.4)

7 (1.8)

354

357 (93.0)

7 (1.8)

14 (3.7)

6 (1.6)

490

250 (90.9)

8 (2.9)

14 (5.1)

3 (1.1)

911

17 (100.0)

0 (0)

0 (0)

0 (0)

1354

416 (89.5)

13 (2.8)

26 (5.6)

10 (2.2)

1416

393 (94.2)

8 (1.9)

9 (2.2)

7 (1.7)

2096

521 (88.0)

12 (2.0)

50 (8.5)

9 (1.5)

2289

539 (93.7)

10 (1.7)

21 (3.7)

5 (0.9)

2578

384 (88.9)

13 (3.0)

24 (5.6)

11 (2.6)

2958

232 (91.3)

4 (1.6)

15 (5.9)

3 (1.2)

3630

271 (90.6)

7 (2.3)

12 (4.0)

9 (3.0)

3697

172 (94.5)

2 (1.1)

4 (2.2)

4 (2.2)

4347

386 (96.0)

2 (0.5)

13 (3.2)

1 (0.3)

4935

395 (89.0)

15 (3.4)

24 (5.4)

10 (2.3)

4967

642 (95.3)

11 (1.6)

13 (1.9)

8 (1.2)

5310

265 (92.3)

4 (1.4)

12 (4.2)

6 (2.1)

5452

658 (93.1)

13 (1.8)

24 (3.4)

12 (1.7)

5783

561 (82.4)

27 (4.0)

54 (7.9)

39 (5.7)

5897

196 (84.9)

4(1.7)

24 (10.4)

7 (3.0)

6061

481 (96.8)

5 (1.0)

9 (1.8)

2 (0.4)

6499

170 (88.5)

4 (2.1)

12 (6.3)

6 (3.1)

6518

459 (84.8)

11 (2.0)

48 (8.9)

23 (4.3)

6713

239 (85.4)

8 (2.9)

20 (7.1)

13 (4.6)

8354

195 (84.8)

8 (3.5)

16 (7.0)

11 (4.8)

8361

487 (87.4)

21 (3.8)

32 (5.8)

17 (3.1)

8646

694 (90.0)

20 (2.5)

49 (6.2)

23 (2.9)

8658

636 (90.0)

19 (2.7)

30 (4.2)

22 (3.1)
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Incident

Prevalent

chronic (N=657) chronic (N=309)

Table 2.6s. (continued)
8660

121 (91.7)

3 (2.3)

4 (3.0)

4 (3.0)

8683

291 (91.2)

7 (2.2)

12 (3.8)

9 (2.8)

8974

277 (84.7)

7 (2.1)

29 (8.9)

14 (4.3)

9637

371 (92.8)

6 (1.5)

20 (5.0)

3 (0.8)

9661

371 (94.6)

2 (0.5)

14 (3.6)

5 (1.3)
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Table 2.7s. Participant characteristics: Included participants vs. participants excluded for
having fewer than 3 visits
Study population

Exclude

(N=13,059)

(N=12,478)

65-74

6,008 (46.01)

5,465 (43.80)

75-84

5,499 (42.11)

5,216 (41.80)

85+

1,552 (11.88)

1,797 (14.40)

Female

7,405 (56.70)

7,069 (56.65)

White

10,829 (83.08)

9,788 (78.92)

Black

1,710 (13.12)

1,892 (15.25)

Other

496 (3.81)

723 (5.83)

15.20 (3.43)

14.57 (3.76)

11,392 (87.23)

10,925 (87.55)

1,014 (7.76)

667 (5.35)

Care facilityc

272 (2.08)

658 (5.27)

Unknown

381 (2.92)

228 (1.83)

Current smoking

438 (3.37)

516 (4.16)

Ever alcohol abuse

582 (4.47)

727 (5.85)

Ever other abused substances

76 (0.58)

140 (1.13)

Agitation

709 (5.44)

1,429 (11.48)

Ever hypertension

7,163 (55.00)

7,149 (57.56)

Ever diabetes

1,618 (12.44)

1,916 (15.40)

Ever cardiovascular disease

3,352 (25.90)

3,519 (28.59)

2,030 (15.58)

2,692 (21.65)

2,229 (17.07)

4,236 (33.95)

990 (7.56)

709 (5.68)

Characteristics
Baseline age

Race

Education, mean (SD)
Type of Residence
Privatea
Independent groupb

Urinary incontinence (ever vs.
never)
Dementia diagnosis
Number of medications
0
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Table 2.7s. (continued)
1 to 4

4,449 (36.60)

4,167 (33.39)

5 or more

7,290 (55.82)

7,602 (60.92)

Antidepressant agent

3,059 (23.42)

3,781 (30.30)

Antipsychotic agent

331 (2.53)

731 (5.86)

1,354 (10.37)

1,604 (12.85)

4,500 (34.46)

4,357 (34.92)

Any opioid use

498 (3.81)

624 (5.00)

Strong opioid use

284 (2.17)

398 (3.19)

Anxiolytic, sedative, or hypnotic
agent
Nonsteroidal anti-inflammatory
medication

(All results presented are N (%) unless otherwise noted)
a=single-or multiple family private living; b=retirement community, or independent
group living; c=assisted living, nursing home, or hospital
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Table 3.1s. Participant characteristics: Included participants vs. participants excluded for
having fewer than 3 visits
Study population

Exclude

(N=8,471)

(N=12,883)

65-74

3,971 (46.9)

5,338 (41.4)

75-84

3,466 (40.9)

5,532 (42.9)

85+

1,034 (12.2)

2,013 (15.6)

5,096 (60.2)

7,221 (56.1)

White

6,920 (81.8)

10,148 (79.2)

Black

1,196 (14.1)

1,963 (15.3)

Other

340 (4.0)

708 (5.5)

15.1 (3.5)

14.5 (3.8)

7,316 (86.4)

11,106 (86.2)

Independent group

686 (8.1)

797 (6.2)

Care facility

223 (2.6)

682 (5.3)

Unknown

246 (2.9)

298 (2.3)

Hypertension

4,679 (55.4)

7,469 (58.2)

Diabetes

1,090 (12.9)

1,988 (15.5)

Cardiovascular disease

2,072 (24.7)

3,784 (29.8)

Urinary incontinence

1,379 (16.3)

2,710 (21.1)

394 (4.7)

816 (6.4)

304 (3.6)

512 (4.0)

4,618 (54.5)

7,551 (58.6)

Antipsychotic agent

266 (3.1)

742 (5.8)

Antidepressant agent

1,920 (22.7)

3,677 (28.5)

Baseline age

Female vs. male
Race

Education (1-year
difference)
Type of Residence
Private

Alcohol or other substance
abuse
Current smoking
Polypharmacy
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Table 3.1s. (continued)
Anxiolytic, sedative, or
hypnotic agent
NSAID
Any opioid use

860 (10.2)

1,558 (12.1)

2,848 (33.6)

4,155 (32.3)

321 (3.8)

633 (4.9)

(All results presented are N (%) unless otherwise noted)
a=single-or multiple family private living; b=retirement community, or independent
group living; c=assisted living, nursing home, or hospital
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Table 3.2s. List of drugs included in “any opioids”
Any opioids: included any opioid analgesic medications
Acetaminophen-codeine

Acetaminophen-hydrocodone'

Acetaminophen-oxycodone

Acetaminophen-tramadol'

Acetaminophen/butalbital/caffeine/
codeine

Acetaminophen/caffeine/dihydrocodeine

Asa/caffeine/propoxyphene

Aspirin/butalbital/caffeine/codeine

Aspirin/caffeine/dihydrocodeine

Aspirin/carisoprodol/codeine'

Aspirin-hydrocodone

Aspirin-oxycodone

Bupivacaine-fentanyl

Bupivacaine-hydromorphone

Buprenorphine

Codeine

Dihydrocodeine

Droperidol-fentanyl

Fentanyl

Fentanyl topical

Fentanyl-ropivacaine

Hydrocodone

Hydrocodone-ibuprofen

Hydromorphone

Meperidine

Methadone

Morphine

Opium

Oxycodone

Oxymorphone

Propoxyphene

Tramadol
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Table 4.1s. Description of variables used in the study
Variables

Cardiovascular
disease

Hypertension
Dementia
COPD
Liver disease
Diabetes
Renal disease
Any malignancy
Metastatic solid
tumor
Alcohol abuse
Drug abuse
Hepatitis C infection
Depression
Psychotic disease

Back pain

Neck pain
Unclassified pain
Arthritis/joint pain

ICD-9 codes
Myocardial infarction: Enhanced ICD-9 Code from Quan et al.
(2005)
Congestive heart failure: Enhanced ICD-9 Code from Quan et
al. (2005)
Peripheral vascular disease: Enhanced ICD-9 Code from Quan
et al. (2005)
Cerebrovascular disease: Enhanced ICD-9 Code from Quan et
al. (2005)
Enhanced ICD-9 code from Quan et al. (2005) including
uncomlicated and complicated
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005), including
mild, moderate, or severe liver disease
Enhanced ICD-9 Code from Quan et al. (2005), including
without and with chronic complication
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005), including
lymphoma and leukemia, except malignant neoplasm of skin
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005)
070.41, 070.44, 070.51, 070.54, V02.62 (Kramer et al., 2008)
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005)
721.3x– 721.9x, 722.2x, 722.30, 722.70, 722.80, 722.90,
722.32, 722.72, 722.82, 722.92, 722.33, 722.73, 722.83,
722.93, 724.xx, 737.1, 737.3, 738.4, 738.5, 739.2, 739.3,
739.4, 756.10, 756.11, 756.12, 756. 13, 756.19, 805.4, 805.8,
839.2, 839.42, 846, 846.0, 847.1, 847.3, 847.2, 847.9 (Sullivan
et al., 2008)
721.0X, 721.1X, 722.0X, 722.31, 722.71, 722.81, 722.91,
723.XX, 839.0, 839.1, 847.0 (Sullivan et al., 2008)
Pelvic pain: 595.1, 625.8, 625.9
Abdominal pain: 564.1
General pain: 338.0, 338.21, 338.29, 338.4, 729.1, 780.96
>=710 and <720 or >=725 and <740 (Sullivan et al., 2008)
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Table 4.1s. (continued)

Neuropathy pain

Migraine/headache
Any fracture

Opportunistic
infection

Surgery history

Tobacco history
Any opioid use

Postherpetic neuropathy: 053.10-053.14, 053.19
Diabetic Neuropathy: 250.60-250.63, 357.2
Neuropathy: 337.00, 337.09, 337.1, 355.1, 356.2, 356.3, 356.4,
356.8, 356.9, 357.1, 357.4, 357.5, 357.6, 357.7, 357.81,
357.89, 357.9, 724.3
Neuralgia: 350.1, 729.2
Surgically induced pain: 338.22, 338.28
Limb pain: 337.20, 337.21, 337.22, 337.29, 353.6, 354.4,
355.0, 355.2, 355.3, 355.4, 355.6, 355.71, 355.79, 355.8,
355.9, 729.5
>=346 and <347, or 307.81 (Sullivan et al., 2008)
800.xx-829.xx
Salmonella septicemia : 003.1
Cryptosporidiosis: 007.2
Other specified protozoal intestinal diseases : 007.8
Tuberculosis (all sites) : 010.0-018
Disease due to other mycobacteria : 031.x
Actinomycotic infections : 039.x
Progressive multifocal leukoencephalopathy: 046.3
Cytomegalovirus : 078.5
Candidiasis (various sites) : 112.0-112
Coccidiomycosis (various sites) : 114.x
Histoplasmosis : 115.x
Crytococcosis : 117.5
Toxoplasmosis : 130.0-130
Pneumocystis Carinii pneumonia: 136.3
Cryptococcal meningitis : 321.0
Pneumonia in cytomegalic inclusion disease: 484.1
(modified from Gebo et al., 2005)
Total Knee Arthroplasty: 27447
Total Hip Arthroplasty: 27130
Laparoscopic Cholecystectomoy: 47562, 47563, 47564
Open Cholecystectomy: 47600, 47605, 47610
Laparoscopic Appendectomy: 44970, 44979
Open Appendectomy: 44950, 44960
Cesarean Section: 59510, 59514, 59515
FESS: 31237, 31240, 31254, 31255, 31256, 31267, 31276,
31287, 31288
Cataract Surgery: 66982, 66983, 66984
TURP: 52601, 52612, 52614
Simple Mastectomy: 19301, 19302, 19303, 19180
(Sun et al., 2016)
305.1
GPI starting with 65
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Table 4.1s. (continued)
Therapeutic class generic product identifier including
Temazepam, Alprazolam, bromazepam, chlordiazepoxide,
clobazam, clonazepam, Clorazepate, Diazepam, Estazolam,
Benzodiazepine
Flunitrazepam, Flurazepam, Halazepam, Ketazolam,
Loprazolam, Lorazepam, Lormetazepam, Medazepam,
Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam,
Temazepam, Triazolam, Midazolam using Medispan
GPI starting with '9654424400' '7260003000' '7299600230'
Gabapentinoid
'6254003000' '6256003020‘ (Gabapentin) and GPI starting with
‘7260005700’ (pregabalin)
Analgesics-anti-inflammatory: GPI starting with 66
Pain medication
Analgesics-nonnarcotic: GPI starting with 64
Antidepressant
GPI starting with 58
Antipsychotic
GPI starting with 59
ICD: International Classification of Disease, 9th Clinical Modification; GPI: Generic
Product Identifiers; NDC: National drug codes
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding
algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med
Care. 2005;43(11):1130-9.
Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in
use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid
insurance plans: the TROUP study. Pain. 2008;138(2):440-9.
Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions,
opportunistic infections, and injection drug use among HIV patients: trends between 1996
and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40(5):609-16.
Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic
Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern
Med. 2016;176(9):1286-93.
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Table 4.2s. Comparing predictors associated with long-term opioid use in Medicaid beneficiaries with HIV using different
models

124

Age
Female
Race
Black vs. white
Other vs. white
Unknown vs. white
State
KY vs. MD
NC vs. MD
WA vs. MD
Cardiovascular disease
HTN
Dementia
COPD
Liver
Diabetes
Renal disease
Any malignancy
Metastatic solid tumor
Hepatitis C infection
Depression
Psychotic disorder
Migraine/headache
Any fracture
Surgery history
Opportunistic infection
Alcohol abuse
Drug abuse
Tobacco use disorder
Back pain
Neck pain
Arthritis

Without clustering
Full Model
Reduced Model
1.02 (1.01,1.03)
1.02 (1.02, 1.03)
1.06 (0.92, 1.22)

State clustering
Full Model
Reduced Model
1.02 (1.01 1.03)
1.02 (1.01, 1.03)
1.06 (0.82, 1.37)

LASSO
Full Model
Reduced Model
1.02 (1.01, 1.03)
1.02 (1.01, 1.03)
1.01 (0.99, 1.02)

0.74 (0.61, 0.90)
0.68 (0.43, 1.08)
0.82 (0.57, 1.20)

0.78 (0.66, 0.92)
0.70 (0.44, 1.10)
0.85 (0.59, 1.22)

0.76 (0.62, 0.93)
0.67 (0.58, 0.79)
0.82 (0.67, 1.01)

0.77 (0.65, 0.91)
0.68 (0.59, 0.78)
0.84 (0.67, 1.05)

0.98 (0.96, 0.99)
0.96 (0.93, 1.00)
0.98 (0.95, 1.01)

0.79 (0.63, 0.99)

0.78 (0.64, 0.96)
1.11 (0.95, 1.30)
0.89 (0.58, 1.36)
1.16 (0.90, 1.50)
0.93 (0.74, 1.16)
0.91 (0.78, 1.05)
0.85 (0.58, 1.25)
1.26 (1.18, 1.35)
1.10 (0.67, 1.83)
1.62 (1.41, 1.87)
0.98 (0.75, 1.30)
0.71 (0.63, 0.80)
0.86 (0.61, 1.21)
0.70 (0.57, 0.87)
1.04 (0.77, 1.39)
1.05 (0.98, 1.13)
0.85 (0.69, 1.03)
1.62 (1.22, 2.16)
0.86 (0.74, 1.00)
1.44 (1.11, 1.88)
1.02 (0.88, 1.17)
1.11 (0.98, 1.26)

0.77 (0.68, 0.88)

0.97 (0.95, 1.00))
1.01 (0.99, 1.03)
0.99 (0.94, 1.03)
1.02 (1.00, 1.03)
0.99 (0.97, 1.02)
0.99 (0.97, 1.01)
0.98 (0.95, 1.01)
1.03 (0.99, 1.06)
1.03 (0.94, 1.11)
1.06 (1.09, 1.04)
1.00 (0.98, 1.02)
0.97 (0.94, 0.99)
0.98 (0.93, 1.03)
0.96 (0.92, 1.01)
1.01 (0.95, 1.07)
1.00 (0.99, 1.02)
0.98 (0.96, 1.00)
1.05 (1.03, 1.07)
0.98 (0.96, 1.01)
1.05 (1.03, 1.07)
1.00 (0.97, 1.04)
1.01 (0.99, 1.03)

0.83 (0.57, 1.19)
0.83 (0.71, 0.98)
0.91 (0.71, 1.17)
0.78 (0.61, 0.98)
1.12 (0.93, 1.34)
0.88 (0.54, 1.44)
1.17 (0.97, 1.40)
0.94 (0.73, 1.21)
0.91 (0.71, 1.18)
0.85 (0.63, 1.15)
1.25 (0.91, 1.73)
1.11 (0.53, 2.30)
1.60 (1.26, 2.02)
0.99 (0.82, 1.18)
0.71 (0.53, 0.96)
0.88 (0.49, 1.57)
0.70 (0.45, 1.10)
1.04 (0.56, 1.93)
1.06 (0.89, 1.26)
0.85 (0.67, 1.09)
1.58 (1.33, 1.87)
0.87 (0.69, 1.10)
1.45 (1.17, 1.79)
1.02 (0.72, 1.45)
1.12 (0.93, 1.35)

1.53 (1.28, 1.84)
0.72 (0.55, 0.95)

1.59 (1.35, 1.86)
1.46 (1.19, 1.80)

1.18 (0.92, 1.51)
0.92 (0.82, 1.02)
1.28 (1.23, 1.33)
1.55 (1.47, 1.64)
0.70 (0.62, 0.79)
0.70 (0.55, 0.89)
1.04 (0.98, 1.11)
0.84 (0.66, 1.05)
1.62 (1.25, 2.12)
1.46 (1.10, 1.93)
1.13 (1.01, 1.25)

0.76 (0.63, 0.90)
0.68 (0.60, 0.77)
0.83 (0.67, 1.03)

1.13 (0.87, 1.48)

1.49 (1.41, 1.57)

1.50 (1.19, 1.90)
1.43 (1.07, 1.93)
1.07 (0.97, 1.19)

Table 4.2s. (continued)
Neuropathy pain
Unclassified pain
Polypharmacy 2 vs. 1
Polypharmacy 3 vs. 1
Pain medication
Benzodiazepine
Gabapentinoid
Antidepressant
Antipsychotic
Any opioid use

1.19 (0.95, 1.49)
1.05 (0.77, 1.43)
1.35 (1.16, 1.57)
1.71 (1.37, 2.14)
1.14 (0.98, 1.33)
1.64 (1.35, 1.99)
1.33 (1.05, 1.69)
1.31 (1.11, 1.54)
1.08 (0.88, 1.33)
1.87 (1.61, 2.17)

1.24 (1.01, 1.51)
1.36 (1.17, 1.58)
1.74 (1.40, 2.16)
1.18 (1.01, 1.37)
1.62 (1.34, 1.96)
1.33 (1.05, 1.68)
1.35 (1.16, 1.56)
1.87 (1.62, 2.15)

1.18 (1.04, 1.33)
1.04 (0.91, 1.20)
1.35 (1.29, 1.41)
1.73 (1.44, 2.08)
1.15 (0.94, 1.41)
1.62 (1.49, 1.76)
1.33 (1.21, 1.46)
1.31 (1.06, 1.62)
1.09 (0.96, 1.24)
1.85 (1.59, 2.15)

1.17 (1.05, 1.30)
1.34 (1.29, 1.40)
1.71 (1.40, 2.09)
1.16 (0.96, 1.40)
1.62 (1.48, 1.77)
1.33 (1.21, 1.45)
1.31 (1.10, 1.56)
1.09 (0.99, 1.21)
1.86 (1.61, 2.13)

1.02 (1.00, 1.04)
1.01 (0.98, 1.04)
1.02 (1.01, 1.04)
1.06 (1.03, 1.08)
1.01 (1.00, 1.03)
1.06 (1.04, 1.09)
1.04 (1.01, 1.07)
1.03 (1.01, 1.04)
1.01 (0.99, 1.03)
1.06 (1.05, 1.08)

1.15 (1.03, 1.29)
1.34 (1.29, 1.40)
1.66 (1.36, 2.03)
1.16 (0.95, 1.42)
1.60 (1.46, 1.76)
1.33 (1.18, 1.49)
1.32 (1.09, 1.60)
1.84 (1.61, 2.10)
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Table 4.3s. Comparing predictors associated with long-term opioid use in male and female Medicaid beneficiaries with HIV
using different models
Male

Age
Race (vs. white)
Black
Other
Unknown
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State
KY vs. MD
NC vs. MD
WA vs. MD
Cardiovascular
disease
Hypertension
Dementia
COPD
Liver

Female

Without clustering
Full Model
Reduced
Model
1.02
1.02
(1.01,1.03)
(1.01, 1.03)

State clustering
Full Model
Reduced
Model
1.02
1.02
(1.00 1.03)
(1.00, 1.03)

Without clustering
Full Model
Reduced
Model
1.03
1.03
(1.02, 1.04)
(1.02, 1.04)

State clustering
Full Model
Reduced
Model
1.03
1.03
(1.02, 1.03)
1.02, 1.03)

0.89
(0.68, 1.17)
0.97
(0.55, 1.73)
0.83
(0.51, 1.36)

0.76
(0.65, 0.90)
0.93
(0.81, 1.06)
0.74
(0.53, 1.03)

0.62
(0.47, 0.82)
0.47
(0.22, 1.01)
0.87
(0.49, 1.55)

0.61
(0.46, 0.81)
0.47
(0.22, 1.02)
0.86
(0.49, 1.53)

0.68
(0.50, 0.93)
0.46
(0.39, 0.54)
0.90
(0.74, 1.11)

0.67
(0.49, 0.91)
0.46
(0.39, 0.55)
0.90
(0.73, 1.11)

0.48
(0.25, 0.90)
0.74
(0.59, 0.92)
0.56 (
0.34, 0.91)
0.77
(0.54, 1.11)
1.06
(0.82, 1.38)
0.84
(0.36, 1.95)
1.25
(0.97, 1.60)
0.78
(0.53, 1.15)

0.49
(0.26, 0.92)
0.71
(0.57, 0.89)
0.58
(0.36, 0.94)
0.79
(0.64, 0.97)
1.06
(0.97, 1.15)
0.84
(0.33, 2.10)
1.26
(0.97, 1.63)
0.77
(0.63, 0.94)

0.79
(0.62, 1.00)
1.08
(1.04, 1.12)

1.25
(0.79, 1.99)
0.95
(0.76, 1.19)
1.26
(0.92, 1.73)
0.77
(0.56, 1.06)
1.19
(0.92, 1.54)
0.90
(0.48, 1.69)
1.07
(0.81, 1.43)
1.09
(0.78, 1.53)

0.76
(0.68, 0.85)
0.93
(0.81, 1.07)
0.74
(0.53, 1.04)

1.31
(0.85, 2.04)
0.94
(0.76, 1.17)
1.34
(1.03, 1.76)
0.77
(0.64, 0.93)
1.16
(0.91, 1.48)
0.92
(0.75, 1.14)
1.06
(0.75, 1.51)
1.07
(0.69, 1.67)

0.78
(0.64, 0.94)
1.16
(0.90, 1.48)
0.92
(0.72, 1.18)

1.25
(0.94, 1.66)
0.75
(0.62, 0.90)

Table 4.3s. (continued)
Diabetes
Renal disease
Any malignancy
Metastatic solid
tumor
Hepatitis C
infection
Depression
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Psychotic
disorder
Migraine/
headache
Any fracture
Surgery history
Opportunistic
infection
Alcohol abuse
Drug abuse
Tobacco use
disorder
Back pain
Neck pain

0.71
(0.49, 1.03)
0.90
(0.61, 1.32)
1.00
(0.64, 1.58)
2.39
(0.93, 6.19)
1.48
(1.08, 2.03)
1.01
(0.77, 1.31)
0.64
(0.42, 0.99)
0.90
(0.37, 2.19)
0.72
(0.41, 1.24)
1.46
(0.61, 3.46)
1.03
(0.81, 1.31)
0.98
(0.72, 1.34)
1.57
(1.23, 2.00)
0.85
(0.62, 1.18)
1.69
(1.27, 2.24)
1.29
(0.82, 2.04)

1.51
(1.17, 1.94)

0.62
(0.41, 0.92)

1.54
(1.22, 1.93)

1.80
(1.37, 2.37)

0.69
(0.50, 0.94)
0.89
(0.68, 1.16)
1.00
(0.95, 1.05)
2.37
(1.28, 4.39)
1.48
(1.21, 1.81)
0.98
(0.62, 1.55)
0.64
(0.51, 0.81)
0.85
(0.42, 1.75)
0.71
(0.43, 1.15)
1.42
(0.96, 2.12)
1.00
(0.86, 1.18)
0.96
(0.81, 1.14)
1.61
(1.34, 1.93)
0.84
(0.74, 0.97)
1.65
(1.06, 2.58)
1.28
(0.95, 1.74)

0.69
(0.50, 0.96)
0.90
(0.70, 1.14)

2.41
(1.29, 4.50)
1.54
(1.44, 1.64)

0.63
(0.56, 0.71)

0.70
(0.43, 1.17)
1.44
(1.04, 1.99)

1.59
(1.38, 1.84)
0.85
(0.74, 0.98)
1.65
(1.02, 2.66)
1.29
(0.95, 1.74)

1.19
(0.84, 1.69)
0.77
(0.47, 1.25)
1.63
(1.01, 2.62)
0.46
(0.14, 1.59)
1.78
(1.25, 2.54)
0.97
(0.75, 1.26)
0.75
(0.50, 1.13)
0.93
(0.43, 2.01)
0.67
(0.31, 1.48)
0.85
(0.34, 2.10)
1.08
(0.85, 1.39)
0.70
(0.47, 1.03)
1.61
(1.26, 2.04)
0.85
(0.59, 1.22)
1.22
(0.88, 1.69)
0.70
(0.39, 1.24)

1.53
(1.16, 2.02)

0.67
(0.46, 0.98)
1.57
(1.24, 1.98)

1.17
(0.77, 1.80)
0.76
(0.45, 1.30)
1.62
(1.24, 2.11)
0.49
(0.29, 0.82)
1.86
(1.61, 2.15)
0.98
(0.83, 1.16)
0.76
(0.60, 0.96)
0.91
(0.72, 1.16)
0.66
(0.39, 1.13)
0.83
(0.62, 1.12)
1.08
(0.88, 1.32)
0.68
(0.32, 1.48)
1.67
(1.08, 2.60)
0.83
(0.65, 1.06)
1.22
(1.07, 1.39)
0.70
(0.36, 1.36)

0.77 (
0.46, 1.26)
1.61
(1.25, 2.07)
0.48
(0.30, 0.76)
1.86
(1.60, 2.16)

0.74
(0.60, 0.92)

0.62
(0.39, 0.99)
0.82
(0.60, 1.12)

1.58
(1.12, 2.22)
0.81
(0.57, 1.15)
1.21
(1.06, 1.38)
0.70
(0.36, 1.37)

Table 4.3s. (continued)
Arthritis
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1.07
(0.83, 1.39)
Neuropathy
1.61
pain
(1.19, 2.18)
Unclassified
1.43
pain
(0.87, 2.35)
Number of medications
1-4 vs. none
1.39
(1.13, 1.72)
5+ vs. none
1.71
(1.27, 2.32)
Pain medication
1.09
(0.87, 1.36)
Benzodiazepine
1.68
(1.29, 2.19)
Gabapentinoid
1.23
(0.89, 1.70)
Antidepressant
1.27
(1.01, 1.59)
Antipsychotic
0.95
(0.70, 1.28)
Any opioid use
1.76
(1.44, 2.16)

1.69
(1.30, 2.19)

1.40
(1.13, 1.73)
1.66
(1.24, 2.23)

1.70
(1.31, 2.20)

1.32
(1.08, 1.62)

1.82
(1.49, 2.20)

1.04
(0.97, 1.13)
1.61
(1.37, 1.90)
1.45
(1.09, 1.94)

1.05
(0.97, 1.13)
1.62
(1.38, 1.90)
1.46
(1.08, 1.98)

1.20
(0.91, 1.58)
0.80
(0.56, 1.14)
0.89
(0.59, 1.32)

1.39
(1.26, 1.53)
1.75
(1.50, 2.05)
1.12
(0.86, 1.47)
1.67
(1.45, 1.93)
1.22
(1.02, 1.47)
1.30
(1.02, 1.65)
0.97
(0.68, 1.38)
1.79
(1.43, 2.25)

1.39
(1.27, 1.52)
1.76
(1.52, 2.02)
1.12
(0.85, 1.47)
1.67
(1.45, 1.93)
1.22
(1.03, 1.44)
1.28
(1.06, 1.54)

1.30
(1.04, 1.63)
1.74
(1.24, 2.43)
1.20
(0.96, 1.49)
1.66
(1.24, 2.22)
1.47
(1.03, 2.10)
1.35
(1.07, 1.72)
1.19
(0.89, 1.60)
2.02
(1.63, 2.50)

1.80
(1.42, 2.27)

1.30
(1.04, 1.62)
1.75
(1.27, 2.43)

1.61
(1.21, 2.14)
1.49
(1.06, 2.10)
1.41
(1.14, 1.75)

2.09
(1.70, 2.56)

1.18
(0.95, 1.47)
0.80
(0.57, 1.12)
0.89
(0.72, 1.10)

1.09
(0.91, 1.32)

1.32
(1.30, 1.33)
1.78
(1.25, 2.54)
1.20
(1.01, 1.42)
1.64
(1.59, 1.69)
1.47
(0.98, 2.20)
1.34
(1.06, 1.70)
1.20
(1.06, 1.36)
2.00
(1.83, 2.19)

1.33
(1.32, 1.33)
1.82
(1.29, 2.58)
1.20
(1.00, 1.45)
1.63
(1.60, 1.66)
1.41
(0.97, 2.05)
1.33
(1.10, 1.60)
1.19
(1.06, 1.35)
2.01
(1.82, 2.21)

0.87
(0.70, 1.10)

Table 5.1s. Minimal sufficient sets based on causal diagram
Model I
V
V
V
V
V

Model II
V
V
V
V
V

Model III
V
V
V
V
V
V

Age
Sex
Race
State
Abuse history
Life Style
Income
Initial Days of supply
Previous opioid use
V
V
V
Tobacco use
V
V
V
Cancer
V
V
V
Charlson Comorbidity
V
V
V
Index (CCI)
Depression
V
V
V
Diabetes
V
V
V
Fall
Fracture
V
V
V
Hepatitis C infection
V
V
Hypertension
V
V
V
Neuropathy and
V
V
V
Neuralgias pain
Opportunistic infection
V
V
Pain disorder
V
Psychotic disorder
V
V
V
Surgery infection
Antidepressant
V
V
V
Antipsychotic
V
V
V
BDZ
V
V
V
Gabapentinoid
Pain killer
V
Polypharmacy
*4 models are additionally available, but includes life style.
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Model IV
V
V
V
V
V

Model V
V
V
V
V
V

V
V
V
V

V
V
V
V

V
V
V
V
V
V
V

V

V

V

V

V
V

V

V

V
V
V
V
V

Table 5.2s. Description of variables included in the study
Variables
Hypertension
Diabetes
Any cancer
Abuse history
Hepatitis C
infection
Depression
Psychotic disease

Pain-related
disease

Neuropathy pain

Any fracture

ICD-9 code
Enhanced ICD-9 code from Quan et al. (2005) including
uncomplicated and complicated
Enhanced ICD-9 Code from Quan et al. (2005), including without
and with chronic complication
Enhanced ICD-9 Code from Quan et al. (2005), including
lymphoma and leukemia, except malignant neoplasm of skin,
metastatic solid tumor
Alcohol abuse and Drug abuse: Enhanced ICD-9 Code from Quan
et al. (2005)
070.41, 070.44, 070.51, 070.54, V02.62 (Kramer et al., 2008)
Enhanced ICD-9 Code from Quan et al. (2005)
Enhanced ICD-9 Code from Quan et al. (2005)
Back pain: 721.3x– 721.9x, 722.2x, 722.30, 722.70, 722.80,
722.90, 722.32, 722.72, 722.82, 722.92, 722.33, 722.73, 722.83,
722.93, 724.xx, 737.1, 737.3, 738.4, 738.5, 739.2, 739.3, 739.4,
756.10, 756.11, 756.12, 756. 13, 756.19, 805.4, 805.8, 839.2,
839.42, 846, 846.0, 847.1, 847.3, 847.2, 847.9 (Sullivan et al.,
2008)
Neck pain: 721.0X, 721.1X, 722.0X, 722.31, 722.71, 722.81,
722.91, 723.XX, 839.0, 839.1, 847.0 (Sullivan et al., 2008)
Pelvic pain: 595.1, 625.8, 625.9
Abdominal pain: 564.1
General pain: 338.0, 338.21, 338.29, 338.4, 729.1, 780.96
Arthritis/joint pain: >=710 and <720 or >=725 and <740 (Sullivan
et al., 2008)
Postherpetic neuropathy: 053.10-053.14, 053.19
Diabetic Neuropathy: 250.60-250.63, 357.2
Neuropathy: 337.00, 337.09, 337.1, 355.1, 356.2, 356.3, 356.4,
356.8, 356.9, 357.1, 357.4, 357.5, 357.6, 357.7, 357.81, 357.89,
357.9, 724.3
Neuralgia: 350.1, 729.2
Surgically induced pain: 338.22, 338.28
Limb pain: 337.20, 337.21, 337.22, 337.29, 353.6, 354.4, 355.0,
355.2, 355.3, 355.4, 355.6, 355.71, 355.79, 355.8, 355.9, 729.5
800.xx-829.xx
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Table 5.2s. (continued)

Opportunistic
infection

Surgery history

Tobacco disorder
Any opioid use
Benzodiazepine
Gabapentinoid
Pain medication
Antidepressant
Antipsychotic

Salmonella septicemia: 003.1
Cryptosporidiosis: 007.2
Other specified protozoal intestinal diseases: 007.8
Tuberculosis (all sites): 010.0-018
Disease due to other mycobacteria: 031.x
Actinomycotic infections: 039.x
Progressive multifocal leukoencephalopathy: 046.3
Cytomegalovirus: 078.5
Candidiasis (various sites): 112.0-112
Coccidiomycosis (various sites): 114.x
Histoplasmosis: 115.x
Crytococcosis: 117.5
Toxoplasmosis: 130.0-130
Pneumocystis Carinii pneumonia: 136.3
Cryptococcal meningitis: 321.0
Pneumonia in cytomegalic inclusion disease: 484.1
(modified from Gebo et al., 2005)
Total Knee Arthroplasty: 27447
Total Hip Arthroplasty: 27130
Laparoscopic Cholecystectomoy: 47562, 47563, 47564
Open Cholecystectomy: 47600, 47605, 47610
Laparoscopic Appendectomy: 44970, 44979
Open Appendectomy: 44950, 44960
Cesarean Section: 59510, 59514, 59515
FESS: 31237, 31240, 31254, 31255, 31256, 31267, 31276,
31287, 31288
Cataract Surgery: 66982, 66983, 66984
TURP: 52601, 52612, 52614
Simple Mastectomy: 19301, 19302, 19303, 19180
(Sun et al., 2016)
ICD-9 code: 305.1
GPI starting with 65
NDC provided by the CDC [106][105][105][105]
GPI starting with '9654424400' '7260003000' '7299600230'
'6254003000' '6256003020‘ (Gabapentin) and GPI starting with
‘7260005700’ (pregabalin)
Analgesics-anti-inflammatory: GPI starting with 66
Analgesics-nonnarcotic: GPI starting with 64
GPI starting with 58
GPI starting with 59

Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The
validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs
administrative databases. Aliment Pharmacol Ther. 2008;27(3):274-82.
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Table 5.2s. (continued)
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding
algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med
Care. 2005;43(11):1130-9.
Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in
use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid
insurance plans: the TROUP study. Pain. 2008;138(2):440-9.
Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions,
opportunistic infections, and injection drug use among HIV patients: trends between 1996
and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40(5):609-16.
Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic
Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern
Med. 2016;176(9):1286-93.
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Table 5.3s. Characteristics of beneficiaries who filled the standard ART prescriptions at
the index date and who did not fill the standard ART prescriptions
Standard ART
(N=655)
43.63 (7.39)
292 (44.7)

Not standard ART
(N=356)
43.14 (8.06)
183 (51.4)

Age
Female (missing=1)
State
KY
23 (3.5)
17 (4.8)
MD
324 (49.5)
182 (51.1)
NC
216 (33.0)
117 (32.9)
WA
92 (14.1)
40 (11.2)
Race
White
185 (28.2)
80 (22.5)
Black
433 (66.1)
252 (70.8)
Other or Unknown
37 (5.7)
24 (6.7)
CCI (mean (SD))
1.31 (1.85)
1.48 (2.06)
Abuse disorder
222 (33.9)
128 (36.0)
Tobacco disorder
96 (14.7)
53 (14.9)
Hepatitis C infection
136 (20.8)
54 (15.2)
Depression
192 (29.3)
99 (27.8)
Diabetes
73 (11.2)
42 (11.8)
Psychotic disease
45 (6.9)
35 (9.8)
Pain related disease
337 (51.5)
196 (55.1)
Neuropathy pain
150 (22.9)
74 (20.8)
Fractures
30 (4.6)
17 (4.8)
Hypertension
183 (27.9)
109 (30.6)
Surgery history
5 (0.8)
4 (1.1)
Opportunistic
138 (21.1)
85 (23.9)
infection
Any Cancer
50 (7.6)
33 (9.3)
Benzodiazepine
148 (22.6)
86 (24.2)
Gabapentinoid
120 (18.3)
52 (14.6)
Pain medication
285 (43.5)
145 (40.7)
Antidepressant
323 (49.3)
147 (41.3)
Antipsychotic
147 (22.4)
79 (22.2)
Any opioid
414 (63.2)
250 (70.2)
Number of medications (excluded opioid and any ART prescriptions)
None
42 (6.4)
41 (11.5)
1-4
169 (25.8)
98 (27.5)
5+
444 (67.8)
217 (61.0)
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p-value
0.34
0.04
0.48

0.13

0.56
0.51
0.92
0.03
0.61
0.75
0.10
0.27
0.44
0.88
0.37
0.56
0.30
0.37
0.57
0.13
0.39
0.01
0.93
0.03
0.01

Figure 5.1s. Causal diagram between long-term opioid use and healthcare utilizations
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